{"gene":"FLCN","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2006,"finding":"FLCN (folliculin) physically interacts with a novel binding protein FNIP1, and this complex associates with AMPK. FNIP1 is phosphorylated by AMPK, and FLCN phosphorylation is reduced by AMPK inhibitors and rapamycin, and enhanced by FNIP1 overexpression, placing FLCN in the AMPK-mTOR signaling axis.","method":"Co-immunoprecipitation, yeast two-hybrid, in vitro phosphorylation assay, pharmacological inhibition (rapamycin, AMPK inhibitors), overexpression studies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro kinase assay, multiple orthogonal methods; independently replicated across subsequent studies","pmids":["17028174"],"is_preprint":false},{"year":2009,"finding":"Homozygous BHD/FLCN knockout in mice causes early embryonic lethality (E5.5–E6.5) with defects in visceral endoderm; heterozygous knockout mice develop kidney tumors with loss of heterozygosity. BHD inactivation leads to activation of both mTORC1 and mTORC2, and PI3K-AKT pathway activation with elevated total AKT protein in kidney tumors.","method":"Conditional knockout mouse model, immunoblotting, LOH analysis, histological analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with defined molecular and cellular phenotypes, multiple orthogonal methods, replicated in human tumor samples","pmids":["19850877"],"is_preprint":false},{"year":2008,"finding":"Kidney-specific FLCN knockout in mice leads to polycystic kidneys, hyperplasia, and cystic renal cell carcinoma via activation of the mTOR pathway; rapamycin treatment rescues these phenotypes, demonstrating FLCN acts upstream to suppress mTOR signaling in kidney.","method":"Conditional knockout mouse model (Ksp-Cre), rapamycin treatment, histological analysis, BUN measurements","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO with pharmacological rescue, multiple phenotypic readouts, independently replicated","pmids":["18974783"],"is_preprint":false},{"year":2010,"finding":"FLCN inactivation induces nuclear localization of TFE3 transcription factor (accompanied by decreased TFE3 phosphorylation), leading to increased TFE3 transcriptional activity and upregulation of its target GPNMB. Restoration of wild-type FLCN suppresses GPNMB expression and nuclear TFE3.","method":"shRNA knockdown, stable re-expression, immunostaining, quantitative RT-PCR, immunoblotting in cell lines, mouse embryo fibroblasts, and mouse/human renal tumors","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function experiments, multiple cell types and in vivo models, multiple orthogonal methods","pmids":["21209915"],"is_preprint":false},{"year":2019,"finding":"Cryo-EM structure of the FLCN-FNIP2-Rag GTPase-Ragulator complex reveals that FLCN-FNIP2 adopts an extended conformation with heterodimerized Longin domains contacting Rag nucleotide-binding domains and DENN domains at the distal end. A conserved arginine on FLCN (catalytic arginine finger) is essential for its GAP activity toward RagC/D GTPases.","method":"Cryo-EM structure determination, biochemical GAP activity assays, mutagenesis of catalytic arginine","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution cryo-EM structure with biochemical and mutagenesis validation in a single rigorous study","pmids":["31704029"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of the active FLCN complex (AFC) with FLCN, FNIP2, SLC38A9 N-terminal tail, RagA(GDP):RagC(GDP·BeFx), and Ragulator shows FLCN reorients 90° relative to its inactive lysosomal conformation, breaks contact with RagA, and makes new contacts with RagC that position Arg164 for catalytic GAP activity. Disruption of AFC-specific interfaces eliminates GAP activity and causes nuclear retention of TFE3 without affecting S6K or 4E-BP1 phosphorylation.","method":"Cryo-EM structure determination, interface mutagenesis, GAP activity assay, TFE3 nuclear localization assay, S6K/4E-BP1 phosphorylation assay","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution cryo-EM with mutagenesis and functional validation demonstrating substrate-selective mTORC1 regulation","pmids":["36103527"],"is_preprint":false},{"year":2012,"finding":"FLCN deficiency in muscle leads to increased mitochondrial biogenesis and a metabolic shift toward oxidative phosphorylation in a PGC-1α (PPARGC1A)-dependent manner. Re-expression of wild-type FLCN in FLCN-null kidney cancer cells suppresses mitochondrial metabolism and PPARGC1A expression.","method":"Tissue-specific conditional knockout mice (CKM-Cre, MYOG-Cre), electron microscopy (% mitochondrial area), metabolic profiling, immunoblotting, PPARGC1A double-knockout epistasis, oxygen consumption measurement","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with genetic epistasis (double KO rescue), multiple orthogonal methods, in vitro and in vivo confirmation","pmids":["23150719"],"is_preprint":false},{"year":2016,"finding":"Adipose-specific deletion of FLCN relieves mTOR-dependent cytoplasmic retention of TFE3, leading to TFE3 nuclear translocation and direct induction of PGC-1α/PGC-1β, driving mitochondrial biogenesis and adipose browning. This is mediated by RagC/D GTPases independently of TSC-mTOR-S6K signaling. Co-deletion of TFE3 or PGC-1β rescues the browning phenotype.","method":"Adipose-specific FLCN KO mice, TFE3 co-deletion epistasis, PGC-1β co-deletion epistasis, TFE3 nuclear localization assay, gene expression analysis, inducible PGC-1β overexpression","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO with multiple genetic epistasis rescue experiments, pathway placement, replicated by independent laboratory","pmids":["27913603"],"is_preprint":false},{"year":2016,"finding":"Loss of FLCN in adipose tissue leads to chronic hyperactivation of AMPK, which induces PGC-1α and ERRα, driving mitochondrial biogenesis, oxidative metabolism, and browning of white adipose tissue. The AMPK/PGC-1α/ERRα molecular axis mediates these metabolic effects.","method":"Adipose-specific FLCN KO mice (Adipoq-FLCN), AMPK activity assays, gene expression analysis, mitochondrial biogenesis assays, metabolic phenotyping (energy expenditure, cold exposure, HFD resistance)","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO with defined pathway placement (AMPK/PGC-1α/ERRα), multiple orthogonal functional readouts","pmids":["27151976"],"is_preprint":false},{"year":2018,"finding":"FLCN-FNIP lysosomal recruitment during amino acid starvation requires GATOR1 GAP activity toward RagA/B (converting them to GDP-bound state). By binding RagA/B(GDP) and acting as GAP on RagC/D, FLCN-FNIP coordinates nucleotide status between Rag heterodimer subunits in response to amino acid availability.","method":"Lysosomal fractionation, dominant-negative and constitutively active Rag GTPase mutants, GATOR1 depletion, fluorescence microscopy, immunoblotting","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and biochemical dissection of pathway order, multiple Rag mutants, replicated by multiple orthogonal approaches","pmids":["29848618"],"is_preprint":false},{"year":2021,"finding":"During autophagy-related processes (CASM, mitophagy, xenophagy), GABARAP (but not LC3) membrane conjugation is required for TFEB/TFE3 activation. GABARAP directly binds to a previously unidentified LIR motif in the FLCN/FNIP complex, sequestering it to GABARAP-conjugated membranes, disrupting FLCN/FNIP GAP function toward RagC/D and impairing mTOR-dependent phosphorylation of TFEB.","method":"Co-immunoprecipitation, LIR motif identification and mutagenesis, GABARAP lipidation assays, TFEB/TFE3 nuclear localization, RagC/D GAP activity assays, selective autophagy genetic models","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding with LIR motif mapping, multiple orthogonal methods, functional consequence on mTOR-TFEB axis demonstrated","pmids":["34597140"],"is_preprint":false},{"year":2014,"finding":"FLCN interacts with GABARAP (GABA-A receptor-associated protein), a core autophagy component. FLCN is phosphorylated by ULK1 at Ser406, Ser537, and Ser542. Loss of FLCN moderately impairs basal autophagic flux. The FLCN-GABARAP interaction is modulated by presence of FNIP1 or FNIP2 and regulated by ULK1.","method":"Co-immunoprecipitation, phosphorylation site mapping, ULK1 overexpression, autophagic flux assays (SQSTM1, MAP1LC3B, GABARAP levels), siRNA knockdown","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with site-specific phosphorylation mapping, single lab, multiple methods","pmids":["25126726"],"is_preprint":false},{"year":2009,"finding":"FLCN phosphorylation at Ser62 and Ser302 is regulated by the Tsc2-mTORC1 pathway downstream of tuberin and Rheb. Downregulation of tuberin or overexpression of Rheb induces multiple FLCN phosphorylations. FLCN phosphorylation modulates its complex formation with AMPK.","method":"Immunoblotting with phospho-specific approaches, siRNA knockdown of TSC2, Rheb overexpression, AMPK co-immunoprecipitation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation mapping with upstream genetic manipulation, single lab, multiple methods","pmids":["19695222"],"is_preprint":false},{"year":2011,"finding":"Pathogenic FLCN missense and in-frame deletion mutations that impair folliculin tumor suppressor function significantly disrupt protein stability (assessed in vitro). Mutations that did not impair protein stability also did not impair growth suppression activity or intracellular localization, indicating protein stability is a functional correlate.","method":"Cycloheximide chase assay, protein stability measurement, growth suppression assay in cell lines, intracellular localization by immunofluorescence, evolutionary analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro stability assays with functional validation for multiple mutants, single lab","pmids":["21538689"],"is_preprint":false},{"year":2010,"finding":"Wild-type FLCN suppresses tumor development in FLCN-null renal cancer cells in nude mice in a dose-dependent manner. FLCN loss leads to downregulation of key TGF-β signaling genes including TGFB2, INHBA, THBS1, GREM1, and SMAD3. Activin A (INHBA homodimer) completely suppresses anchorage-independent growth of FLCN-null cells.","method":"Xenograft tumor assay, differential gene expression, ELISA for secreted proteins, anchorage-independent growth assay, FLCN stable re-expression","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo xenograft with molecular rescue, multiple pathway readouts, single lab","pmids":["20573232"],"is_preprint":false},{"year":2019,"finding":"FLCN and AMPK act upstream of TFEB/TFE3 in the innate immune response independently of the mTORC1 signaling pathway. In C. elegans, loss of FLCN confers pathogen resistance via AMPK-dependent TFEB/TFE3 activation. In mammalian cells, loss of FLCN or AMPK activation induces TFEB/TFE3-dependent pro-inflammatory cytokine expression. LPS treatment of macrophages reduces ATP and activates AMPK with concomitant TFEB nuclear localization.","method":"C. elegans genetic epistasis (flcn-1 deletion, AMPK overexpression/deletion), mammalian FLCN KO cells, pharmacological AMPK activation, LPS treatment, nuclear localization assays, cytokine expression measurement","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cross-species genetic epistasis, multiple orthogonal approaches, both C. elegans and mammalian models used","pmids":["30917316"],"is_preprint":false},{"year":2015,"finding":"In C. elegans, FLCN-1 (FLCN ortholog) loss leads to constitutive AMPK-dependent accumulation of glycogen stores, conferring resistance to hyperosmotic stress. Upon stress, glycogen is degraded to produce glycerol through GPDH enzymes. This resistance requires AMPK, glycogen synthase, and glycogen phosphorylase. Glycogen accumulates in kidneys of FLCN-deficient mice and renal tumors from BHD patients.","method":"C. elegans genetics (loss-of-function mutations, epistasis), glycogen measurement, glycerol production assay, GPDH enzyme inhibition, mouse kidney histology, human tumor tissue analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — C. elegans genetic epistasis with mammalian model validation, multiple methods, single lab","pmids":["26439621"],"is_preprint":false},{"year":2011,"finding":"The AMPK-MAPO1(FNIP2)-FLCN complex is required for apoptosis triggered by O6-methylguanine DNA damage. siRNA knockdown of FLCN or FNIP2/MAPO1 suppresses sub-G1 accumulation after MNU treatment. AMPK phosphorylation after MNU occurs in an MLH1-dependent manner and requires both MAPO1 and FLCN for normal AMPK activation.","method":"siRNA knockdown, cell cycle analysis (sub-G1), AMPK phosphorylation immunoblotting, AICAR treatment, mitochondrial membrane potential assay","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA-based loss-of-function with multiple functional readouts, single lab, mechanistically placed in DNA damage apoptosis pathway","pmids":["22209521"],"is_preprint":false},{"year":2014,"finding":"Loss of FLCN in cardiomyocytes causes severe cardiac hypertrophy via mTORC1 upregulation. Flcn-deficient hearts show reduced phospho-AMPK-α (T172), elevated ATP, and increased mitochondrial function. Upregulated PPARGC1A (PGC-1α) drives excess mitochondrial metabolism, leading to AMPK inactivation and mTORC1 activation. Inactivation of PPARGC1A in Flcn-deficient hearts reduces heart mass, restores phospho-AMPK, and suppresses mTORC1.","method":"Cardiac-specific FLCN KO mice, PPARGC1A double KO epistasis, rapamycin treatment, AMPK activity assays, ATP measurement, mitochondrial function assays, echocardiography","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO with genetic epistasis (double KO rescue) and pharmacological rescue, multiple orthogonal methods","pmids":["24908670"],"is_preprint":false},{"year":2006,"finding":"Drosophila BHD homolog (DBHD) is required for germline stem cell (GSC) maintenance in fly testis. RNAi-mediated reduction of DBHD suppresses the GSC overproliferation phenotype caused by overexpression of the JAK/STAT ligand unpaired (upd) or the Dpp pathway, placing DBHD downstream or in parallel of JAK/STAT and Dpp signaling in GSC regulation.","method":"RNAi knockdown, genetic epistasis with JAK/STAT and Dpp pathway components, germline stem cell counting in fly testis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo Drosophila genetic epistasis, multiple pathway interactions tested, single lab, ortholog evidence","pmids":["16636660"],"is_preprint":false},{"year":2019,"finding":"AMPK promotes expression of the FLCN tumor suppressor gene through activation of TFEB independently of mTOR. AMPK-induced FLCN expression is abolished in cells lacking TFEB/TFE3, and mutation of the putative TFEB-binding site in the FLCN promoter abrogates promoter activity, defining an AMPK-TFEB-FLCN transcriptional axis.","method":"Transcriptomic profiling, AMPK-deficient MEFs, pharmacological AMPK activators, TFEB/TFE3 double KO, FLCN promoter-luciferase reporter assay with TFEB site mutation, zebrafish exercise model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with mutagenesis, genetic KO validation, cross-species conservation, single lab","pmids":["31404503"],"is_preprint":false},{"year":2020,"finding":"FLCN loss in hematopoietic cells disrupts a FLCN-TFE3 feedback loop: TFE3 normally transcriptionally activates FLCN expression, and loss of FLCN amplifies TFE3 activity. TFE3 stimulates glycogenesis by promoting expression of glycogenesis genes (Gys1, Gyg). TFE3 deletion in Flcn-KO mice reduces phagocyte expansion and lysosomal storage disorder-like phenotypes.","method":"Hematopoietic-specific Flcn KO mice, Tfe3 co-deletion epistasis, transcriptional target analysis (ChIP/gene expression), glycogen accumulation assays, histological analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with double KO rescue, mechanistic pathway placement, single lab","pmids":["32049013"],"is_preprint":false},{"year":2020,"finding":"Genetic deficiency of Folliculin in mice causes misconnection of blood and lymphatic vessels due to ectopic expression of Prox1 in venous endothelial cells. Mechanistically, FLCN loss leads to nuclear translocation of TFE3, which binds a regulatory element of the Prox1 gene to enhance its venous expression.","method":"Endothelial-specific FLCN KO mice, TFE3 nuclear localization by immunofluorescence, ChIP assay for TFE3 binding to Prox1 regulatory element, Prox1 expression analysis, vascular anatomy analysis in mice and humans","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with ChIP-based mechanistic validation of TFE3-Prox1 axis, human and mouse data, multiple orthogonal methods","pmids":["33298956"],"is_preprint":false},{"year":2016,"finding":"FLCN maintains the leucine level within lysosomes to stimulate mTORC1. FLCN suppression reduces lysosomal leucine content and mTORC1 activity; both effects are reversed by high leucine supplementation but not other amino acids. FLCN exerts this function by inhibiting accumulation of the amino acid transporter PAT1 on the lysosome surface.","method":"FLCN knockdown/overexpression in HEK293 cells, lysosomal amino acid measurement, mTORC1 activity assay (S6K phosphorylation), PAT1 localization by immunofluorescence, leucine rescue experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical measurement of lysosomal leucine with functional rescue, PAT1 localization studies, single lab","pmids":["27280402"],"is_preprint":false},{"year":2018,"finding":"FLCN interacts with Rab11A through its C-terminal DENN-like domain. FLCN promotes loading of the amino acid transporter PAT1 onto Rab11A vesicles for recycling to the plasma membrane, preventing PAT1 accumulation on lysosomes and maintaining lysosomal amino acid levels for mTORC1 activation. In vitro GEF activity assay does not support direct FLCN-mediated modification of Rab11A nucleotide state.","method":"Co-immunoprecipitation, domain-mapping pulldown, PAT1 localization by immunofluorescence, mTORC1 activity assay, in vitro GEF assay (negative result for direct GEF activity on Rab11A), siRNA knockdown","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and functional consequences, negative GEF result explicitly noted, single lab","pmids":["30446510"],"is_preprint":false},{"year":2021,"finding":"FLCN promotes Rab11A binding with transferrin receptor 1 (TfR1), which is required for TfR1 recycling between cell surface and cytoplasm. Loss of FLCN attenuates Rab11A-TfR1 interaction, delays TfR1 recycling, causes iron deficiency, and induces HIF activity. Iron supplementation reverses the HIF activation, and iron-rich diet rescues BHD phenotypes in Drosophila.","method":"Co-immunoprecipitation (Rab11A-TfR1), TfR1 recycling assay, HIF activity reporter, iron measurement, siRNA knockdown, Drosophila BHD model with dietary iron rescue","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for complex, functional recycling assay, cross-species rescue, single lab","pmids":["33609526"],"is_preprint":false},{"year":2015,"finding":"FLCN-null cells exhibit dysregulated cofilin de/phosphorylation pathways. SSH2 serine phosphatase knockdown specifically induces Caspase3/7-dependent apoptosis in FLCN-deficient cells but not in isogenic FLCN-expressing cells, identifying a synthetic lethal interaction between FLCN loss and SSH2.","method":"siRNA library screening, Caspase3/7 activity assay, cell cycle analysis, SSH1/2/3 expression measurement, FLCN isogenic cell line comparison","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — synthetic lethality screen with mechanistic follow-up in isogenic cell lines, cofilin pathway measurement, single lab","pmids":["23416984"],"is_preprint":false},{"year":2019,"finding":"Loss of FLCN in human renal tubular epithelial cells activates TFE3 and upregulates its E-box targets RRAGD and GPNMB without modifying mTORC1 activity. FLCN loss or loss of its binding partners FNIP1/FNIP2 induces a non-canonical interferon response independently of interferon, involving STAT2 recruitment to chromatin and slowed cellular proliferation.","method":"FLCN/FNIP1/FNIP2 CRISPR knockout in RPTEC/TERT1 cells, RNA-seq, ChIP for STAT2, mTORC1 activity assays, TFE3 target gene expression, proliferation assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with integrated multi-omic analysis and ChIP mechanistic validation, single lab","pmids":["33459596"],"is_preprint":false},{"year":2019,"finding":"Loss of FLCN inhibits canonical WNT signaling via TFE3. FLCN deficiency decreases expression of Wnt2, Wnt7b, TCF4, LEF1, BCL9, AXIN2, and BMP4. Constitutively active β-catenin only partially rescues decreased WNT activity, whereas silencing TFE3 completely reverses the WNT activity deficit in FLCN-deficient cells, placing TFE3 as a key mediator of FLCN-dependent WNT regulation.","method":"Flcn inactivation in MEFs and human fetal lung fibroblasts, RNA-seq, TCF/LEF luciferase reporter assay, TFE3 siRNA epistasis, constitutively active β-catenin rescue","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with TFE3 silencing rescue, reporter assay, single lab","pmids":["31272105"],"is_preprint":false},{"year":2015,"finding":"FLCN is a novel modifier of TDP-43 cytoplasmic translocation and aggregation. FLCN directly interacts with TDP-43 through FLCN amino acids 202-299 and the RNA-recognition motif domains of TDP-43. Both exogenous and endogenous FLCN are required for TDP-43 cytoplasmic accumulation, protein aggregation, and stress granule formation.","method":"Co-immunoprecipitation, domain-mapping truncation assays, siRNA knockdown, overexpression, immunofluorescence for TDP-43 localization and aggregation, stress granule assay","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, loss-of-function phenotype in multiple conditions, single lab","pmids":["26516189"],"is_preprint":false},{"year":2023,"finding":"AKT1 phosphorylates FLCN at a conserved site (Ser62) in an insulin-responsive manner. mTORC2-AKT1 is recruited to lysosomes by RagD, and this lysosomal RagD-mTORC2-AKT1 recruitment is an essential step for insulin-stimulated FLCN phosphorylation. FLCN phosphorylation inhibits RagC GAP activity and is required for insulin-induced mTORC1 activation and promotes tumor growth in an mTORC1-dependent manner.","method":"In vitro kinase assay (AKT1 phosphorylation of FLCN), lysosomal fractionation, RagD mutant studies, mTORC1 activity assay, FLCN phospho-site mutagenesis, xenograft tumor model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay with mutagenesis and in vivo xenograft validation, single lab","pmids":["37083230"],"is_preprint":false},{"year":2021,"finding":"Loss of hepatic FLCN activates TFEB and TFE3, promoting autophagy, reducing triglyceride accumulation, fibrosis, and inflammation in a methionine- and choline-deficient diet liver disease model.","method":"Liver-specific FLCN KO mice, TFEB/TFE3 nuclear localization assay, autophagic flux measurement, lipid accumulation assay, fibrosis scoring, inflammatory marker assessment","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with functional mechanistic readouts, single lab","pmids":["34711912"],"is_preprint":false},{"year":2017,"finding":"FLCN missense mutants H255Y and K508R promote aberrant kidney cell proliferation. H255Y mutant transgene expression fails to rescue the multi-cystic kidney phenotype of Flcn-deficient mice. K508R mutant transgene partially rescues the phenotype in full KO mice but induces multi-cystic kidneys and cardiac hypertrophy in heterozygous KO mice, suggesting dominant negative activity of K508R on wild-type FLCN.","method":"BAC recombineering transgenic mice, Flcn-KO kidney phenotype rescue assay, histological analysis, cardiac phenotyping","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic rescue assay with multiple mutants and genetic contexts, single lab","pmids":["28007907"],"is_preprint":false},{"year":2017,"finding":"FNIP2 protein stability is regulated by SCFβ-TRCP E3 ubiquitin ligase and Casein Kinase 1 (CK1) in a nutrition-dependent manner. Degradation of FNIP2 leads to lysosomal dissociation of FLCN and subsequent lysosomal association of mTOR, promoting renal cancer cell proliferation.","method":"Proteasome inhibitor experiments, β-TRCP and CK1 inhibition/knockdown, ubiquitination assays, lysosomal fractionation for FLCN and mTOR localization, proliferation assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay with upstream kinase identification and lysosomal localization consequence, single lab","pmids":["28039480"],"is_preprint":false},{"year":2023,"finding":"PRDM10 directly binds a regulatory motif in the FLCN promoter and controls FLCN transcription. The PRDM10 Cys677Tyr variant loses affinity for this FLCN promoter element, abrogating FLCN mRNA and protein levels in human cells.","method":"DNA binding assay for PRDM10 at FLCN promoter, promoter reporter assay, inducible PRDM10 Cys677Tyr overexpression, RNA-seq, FLCN protein quantification","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding with functional consequence on FLCN expression, single lab, co-segregation in family","pmids":["36440963"],"is_preprint":false}],"current_model":"FLCN (folliculin) is a tumor suppressor that functions as a GAP (GTPase-activating protein) for RagC/D GTPases within the FLCN-FNIP1/2 heterodimer; by catalyzing GTP hydrolysis on RagC/D at the lysosomal surface (positioning its arginine finger Arg164 for catalysis as revealed by cryo-EM structures), FLCN enables mTORC1 activation in response to amino acids and specifically controls mTOR-dependent phosphorylation of the MiT/TFE transcription factors (TFE3, TFEB), thereby regulating lysosomal biogenesis, autophagy, mitochondrial biogenesis via PGC-1α/ERRα, adipose browning, glycogen metabolism, iron homeostasis via Rab11A-TfR1 recycling, innate immune signaling via AMPK-TFEB, WNT signaling, and blood-lymphatic vessel segregation; FLCN is itself phosphorylated by both mTORC1/unknown kinases (at Ser62 and Ser302) and by AKT1 (at Ser62 in response to insulin) and by ULK1 (at Ser406, Ser537, Ser542), and its lysosomal recruitment is gated by GATOR1-dependent conversion of RagA/B to the GDP-bound state, while its sequestration by GABARAP during autophagy disrupts its GAP function to activate TFEB/TFE3."},"narrative":{"mechanistic_narrative":"FLCN (folliculin) is a tumor suppressor that operates at the lysosomal surface as the catalytic GTPase-activating protein (GAP) for RagC/D within the amino acid-sensing arm of the mTORC1 pathway, coupling nutrient status to a transcriptional program governed by the MiT/TFE factors TFE3 and TFEB [PMID:31704029, PMID:36103527, PMID:27913603]. FLCN acts in an obligate heterodimer with FNIP1/FNIP2 and, in its active conformation, reorients to position a catalytic arginine finger (Arg164) for GTP hydrolysis on RagC/D; disruption of this active interface abolishes GAP activity and drives nuclear retention of TFE3 without affecting canonical S6K/4E-BP1 phosphorylation, defining a substrate-selective mode of mTORC1 control [PMID:31704029, PMID:36103527]. Lysosomal recruitment of the FLCN-FNIP complex is gated by amino acid availability through GATOR1-dependent conversion of RagA/B to the GDP-bound state, and FLCN coordinates the nucleotide status of the two Rag subunits by binding RagA/B(GDP) while acting as GAP on RagC/D [PMID:29848618]. Loss of FLCN relieves mTOR-dependent cytoplasmic sequestration of TFE3/TFEB, and the resulting nuclear MiT/TFE activity is the common driver of FLCN-deficiency phenotypes: induction of PGC-1α/PGC-1β driving mitochondrial biogenesis and adipose browning [PMID:27913603], chronic AMPK–PGC-1α/ERRα activation [PMID:27151976], glycogen accumulation [PMID:26439621, PMID:32049013], cardiac hypertrophy [PMID:24908670], a non-canonical interferon response [PMID:33459596], WNT pathway modulation [PMID:31272105], and ectopic Prox1 expression causing blood–lymphatic vessel misconnection through direct TFE3 binding to a Prox1 regulatory element [PMID:33298956]. In vivo, FLCN loss activates mTORC1 (and PI3K-AKT) and produces polycystic kidneys and renal cell carcinoma that are rescued by rapamycin, establishing FLCN as an upstream suppressor of mTOR in the kidney [PMID:19850877, PMID:18974783]. FLCN sits within feedback and stress-responsive circuits: AMPK–TFEB transcriptionally induces FLCN expression, TFE3 itself activates FLCN transcription, and PRDM10 directly drives FLCN promoter activity [PMID:31404503, PMID:32049013, PMID:36440963]. FLCN activity is further tuned by phosphorylation—by the TSC2-mTORC1 axis at Ser62/Ser302, by ULK1 at Ser406/Ser537/Ser542, and by insulin-responsive mTORC2–AKT1 at Ser62, the latter inhibiting RagC GAP activity to promote insulin-induced mTORC1 activation and tumor growth [PMID:25126726, PMID:19695222, PMID:37083230]. Beyond the lysosome, FLCN engages Rab11A through its C-terminal DENN-like domain to promote recycling of PAT1 and transferrin receptor 1, maintaining lysosomal amino acid levels and iron homeostasis [PMID:30446510, PMID:33609526].","teleology":[{"year":2006,"claim":"Establishing that FLCN works through a defined protein complex and signaling axis was the first step in moving beyond its identification as a BHD disease gene; FNIP1 was shown to be its physical partner linking FLCN to AMPK-mTOR signaling.","evidence":"Yeast two-hybrid and reciprocal Co-IP with in vitro kinase assays and pharmacological inhibition in mammalian cells","pmids":["17028174"],"confidence":"High","gaps":["Did not define the direction of FLCN's effect on mTOR","Kinase phosphorylating FLCN not identified","No structural or catalytic mechanism"]},{"year":2008,"claim":"Whether FLCN suppresses or promotes mTOR in vivo was resolved by tissue-specific knockout showing FLCN acts upstream to restrain mTOR in the kidney, with rapamycin reversing the cystic tumor phenotype.","evidence":"Kidney-specific conditional KO mice with rapamycin rescue and histology","pmids":["18974783"],"confidence":"High","gaps":["Did not define the biochemical activity by which FLCN suppresses mTOR","Did not identify the relevant downstream effectors"]},{"year":2009,"claim":"Germline and heterozygous mouse models established FLCN as a bona fide tumor suppressor with LOH-driven kidney tumors and showed FLCN loss activates both mTORC1/mTORC2 and PI3K-AKT, placing it broadly in growth-signaling control.","evidence":"Conditional KO mice, LOH analysis, immunoblotting of human tumors","pmids":["19850877"],"confidence":"High","gaps":["Mechanism connecting FLCN loss to AKT/mTORC2 not resolved","Essential embryonic role not mechanistically dissected"]},{"year":2010,"claim":"The key downstream effector of FLCN was identified as the MiT/TFE transcription factor TFE3, whose phosphorylation and cytoplasmic retention depend on FLCN, with TFE3 targets (e.g. GPNMB) induced upon FLCN loss.","evidence":"shRNA knockdown and re-expression with immunostaining, RT-PCR across cell lines, MEFs, and tumors","pmids":["21209915"],"confidence":"High","gaps":["The biochemical step linking FLCN to TFE3 phosphorylation not yet defined","Relationship to canonical mTORC1 substrates unclear"]},{"year":2010,"claim":"Beyond mTOR, FLCN re-expression was shown to suppress tumor growth and modulate TGF-β pathway genes, with Activin A blocking anchorage-independent growth, broadening the tumor-suppressor output.","evidence":"Xenograft assays, differential gene expression, ELISA, anchorage-independent growth with FLCN re-expression","pmids":["20573232"],"confidence":"Medium","gaps":["Direct mechanism linking FLCN to TGF-β gene expression not established","Relationship to the TFE3 axis not resolved"]},{"year":2012,"claim":"FLCN was linked to mitochondrial metabolism by showing its deficiency drives PGC-1α-dependent mitochondrial biogenesis and oxidative metabolism, with PGC-1α double-KO epistasis confirming the axis.","evidence":"Muscle-specific conditional KO mice, PPARGC1A double-KO epistasis, EM and metabolic profiling","pmids":["23150719"],"confidence":"High","gaps":["How FLCN loss elevates PGC-1α not mechanistically traced","Connection to TFE3/mTOR left open"]},{"year":2014,"claim":"FLCN was tied directly to the core autophagy machinery via GABARAP binding and ULK1-mediated phosphorylation, embedding it in autophagy regulation.","evidence":"Co-IP, phospho-site mapping, ULK1 overexpression, autophagic flux assays","pmids":["25126726"],"confidence":"Medium","gaps":["Functional consequence of ULK1 phosphorylation on GAP activity not defined here","Single-lab finding"]},{"year":2016,"claim":"The TFE3-PGC-1 connection was placed firmly downstream of FLCN's RagC/D activity in adipose browning, independent of TSC-mTOR-S6K, by multiple epistasis rescues.","evidence":"Adipose-specific KO mice with TFE3 and PGC-1β co-deletion epistasis and inducible overexpression","pmids":["27913603"],"confidence":"High","gaps":["Did not yet provide structural proof of RagC/D GAP activity","Parallel AMPK contribution not reconciled"]},{"year":2016,"claim":"A parallel route to FLCN-deficiency metabolism was defined through chronic AMPK–PGC-1α–ERRα activation driving browning and oxidative metabolism.","evidence":"Adipose-specific KO mice, AMPK activity assays, metabolic phenotyping","pmids":["27151976"],"confidence":"High","gaps":["Mechanistic integration of AMPK and TFE3 arms left unresolved","Cause of AMPK hyperactivation not fully traced"]},{"year":2016,"claim":"A biochemical role at the lysosome was proposed by showing FLCN maintains lysosomal leucine to stimulate mTORC1 by limiting lysosomal PAT1 accumulation.","evidence":"Knockdown/overexpression in HEK293, lysosomal amino acid measurement, mTORC1 assays, leucine rescue","pmids":["27280402"],"confidence":"Medium","gaps":["Mechanism preventing PAT1 lysosomal accumulation not yet defined","Relationship to GAP activity unclear"]},{"year":2018,"claim":"The gating of FLCN-FNIP recruitment was resolved: GATOR1 GAP activity on RagA/B (GDP loading) recruits the complex, which then acts as GAP on RagC/D, coordinating nucleotide status across the Rag heterodimer with amino acid availability.","evidence":"Lysosomal fractionation, dominant-negative/constitutively active Rag mutants, GATOR1 depletion, microscopy","pmids":["29848618"],"confidence":"High","gaps":["Atomic mechanism of catalysis not yet shown","How nutrient signals trigger reorientation unresolved"]},{"year":2018,"claim":"The PAT1-recycling mechanism was clarified by identifying FLCN's C-terminal DENN-like domain interaction with Rab11A that loads PAT1 onto recycling vesicles, with FLCN not acting as a direct Rab11A GEF.","evidence":"Co-IP, domain mapping, PAT1 localization, mTORC1 assays, in vitro GEF assay (negative)","pmids":["30446510"],"confidence":"Medium","gaps":["Precise enzymatic role on Rab11A unresolved (no GEF activity)","Single-lab finding"]},{"year":2019,"claim":"Atomic-level mechanism was established: cryo-EM of the FLCN-FNIP2-Rag-Ragulator complex revealed the heterodimer architecture and a conserved catalytic arginine finger essential for RagC/D GAP activity.","evidence":"Cryo-EM structure with biochemical GAP assays and arginine-finger mutagenesis","pmids":["31704029"],"confidence":"High","gaps":["Captured an inactive conformation; catalytic geometry not yet seen","How conformational switching is triggered not resolved"]},{"year":2019,"claim":"FLCN was extended into innate immunity and stress, acting with AMPK upstream of TFEB/TFE3 independently of mTORC1 to drive pro-inflammatory and pathogen-resistance programs across species.","evidence":"C. elegans genetic epistasis and mammalian KO cells with AMPK activation and LPS treatment","pmids":["30917316"],"confidence":"High","gaps":["mTOR-independent route to TFEB activation not biochemically defined","Direct AMPK-FLCN-TFEB connectivity not mapped"]},{"year":2019,"claim":"A transcriptional feedback loop was uncovered whereby AMPK induces FLCN expression via TFEB binding a defined FLCN promoter element, independent of mTOR.","evidence":"Transcriptomics, AMPK-deficient MEFs, TFEB/TFE3 KO, FLCN promoter-luciferase with site mutation, zebrafish","pmids":["31404503"],"confidence":"Medium","gaps":["Physiological contexts engaging the loop not fully defined","Single-lab reporter evidence"]},{"year":2019,"claim":"FLCN was linked to WNT signaling, with TFE3 silencing fully reversing the WNT-activity deficit of FLCN-deficient cells, identifying TFE3 as the key mediator.","evidence":"Flcn inactivation in MEFs/fibroblasts, RNA-seq, TCF/LEF reporter, TFE3 siRNA epistasis, β-catenin rescue","pmids":["31272105"],"confidence":"Medium","gaps":["Direct TFE3 targets in the WNT pathway not mapped","Single-lab finding"]},{"year":2020,"claim":"A developmental role was defined: FLCN loss drives TFE3-dependent ectopic Prox1 expression in venous endothelium, causing blood-lymphatic vessel misconnection, with ChIP showing direct TFE3 binding to a Prox1 regulatory element.","evidence":"Endothelial-specific KO mice, ChIP for TFE3-Prox1, vascular anatomy in mice and humans","pmids":["33298956"],"confidence":"High","gaps":["How FLCN loss is sensed specifically in venous endothelium not resolved"]},{"year":2020,"claim":"A FLCN-TFE3 feedback loop in hematopoietic cells was defined where TFE3 transcriptionally activates FLCN and FLCN loss amplifies TFE3-driven glycogenesis and lysosomal-storage-like phenotypes.","evidence":"Hematopoietic-specific KO mice with Tfe3 co-deletion epistasis and transcriptional target analysis","pmids":["32049013"],"confidence":"Medium","gaps":["Generality of the feedback loop across tissues not established","Single-lab finding"]},{"year":2021,"claim":"A regulatory off-switch was identified: during selective autophagy (CASM/mitophagy/xenophagy), GABARAP conjugation sequesters FLCN-FNIP via a LIR motif, disrupting RagC/D GAP function to activate TFEB/TFE3.","evidence":"Co-IP, LIR motif mapping/mutagenesis, GABARAP lipidation assays, GAP and nuclear-localization assays","pmids":["34597140"],"confidence":"High","gaps":["In vivo significance of GABARAP-mediated FLCN sequestration not quantified","LC3 vs GABARAP selectivity mechanism not fully defined"]},{"year":2021,"claim":"FLCN was connected to iron homeostasis by promoting Rab11A-TfR1 binding required for TfR1 recycling; FLCN loss causes iron deficiency and HIF activation rescued by dietary iron.","evidence":"Co-IP, TfR1 recycling and HIF reporter assays, Drosophila BHD model with iron rescue","pmids":["33609526"],"confidence":"Medium","gaps":["Whether iron deficiency contributes to BHD tumorigenesis unresolved","Single-lab finding"]},{"year":2021,"claim":"A hepatic role was defined where FLCN loss activates TFEB/TFE3 to promote autophagy and reduce steatosis, fibrosis and inflammation in a fatty liver model.","evidence":"Liver-specific KO mice with autophagy, lipid, fibrosis and inflammation readouts","pmids":["34711912"],"confidence":"Medium","gaps":["Direct transcriptional targets driving the protective phenotype not mapped"]},{"year":2022,"claim":"The catalytic mechanism of substrate-selective mTORC1 control was visualized: in the active FLCN complex, FLCN reorients 90° to break RagA contacts and engage RagC, positioning Arg164 for catalysis; disrupting this interface abolishes GAP activity and retains TFE3 in the nucleus without affecting S6K/4E-BP1.","evidence":"Cryo-EM of the active complex, interface mutagenesis, GAP and TFE3/S6K assays","pmids":["36103527"],"confidence":"High","gaps":["Trigger for the inactive-to-active conformational switch not fully defined","Basis of TFE3 vs S6K substrate selectivity at the catalytic step incomplete"]},{"year":2023,"claim":"Insulin-responsive regulation of FLCN was defined: lysosomal RagD-recruited mTORC2-AKT1 phosphorylates FLCN at Ser62, inhibiting RagC GAP activity to enable insulin-induced mTORC1 activation and tumor growth.","evidence":"In vitro AKT1 kinase assay, lysosomal fractionation, RagD mutants, phospho-site mutagenesis, xenografts","pmids":["37083230"],"confidence":"Medium","gaps":["Reconciliation of AKT1 Ser62 with TSC2-mTORC1 Ser62/Ser302 phosphorylation incomplete","Single-lab finding"]},{"year":2023,"claim":"Transcriptional control of FLCN was extended by showing PRDM10 directly binds the FLCN promoter, with a pathogenic Cys677Tyr variant abrogating FLCN expression.","evidence":"PRDM10 DNA binding and promoter reporter assays, inducible variant expression, RNA-seq, family co-segregation","pmids":["36440963"],"confidence":"Medium","gaps":["Broader regulatory network controlling FLCN expression not mapped"]},{"year":null,"claim":"It remains unresolved how a single FLCN-FNIP RagC/D GAP activity is mechanistically partitioned to selectively control MiT/TFE phosphorylation versus canonical mTORC1 substrates, and how the multiple inputs (ULK1, AKT1/mTORC2, TSC2-mTORC1 phosphorylation; GABARAP sequestration; GATOR1 gating) are integrated in a given tissue.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model reconciling phosphorylation inputs with conformational switching","Substrate-selectivity mechanism at the catalytic step undefined","Tissue-specific weighting of mTOR-dependent vs AMPK/mTOR-independent TFE3/TFEB arms unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,9]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,24,25]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[5,9,23,33]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[24,25]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,5,9]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[3,5,7,22]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[10,11,31]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[6,8,16,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,32]}],"complexes":["FLCN-FNIP1/2 heterodimer","FLCN-FNIP2-Rag-Ragulator (active FLCN complex)","AMPK-FNIP2(MAPO1)-FLCN complex"],"partners":["FNIP1","FNIP2","RAGC","RAGA","GABARAP","RAB11A","TDP-43","AKT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8NFG4","full_name":"Folliculin","aliases":["BHD skin lesion fibrofolliculoma protein","Birt-Hogg-Dube syndrome protein"],"length_aa":579,"mass_kda":64.5,"function":"Multi-functional protein, involved in both the cellular response to amino acid availability and in the regulation of glycolysis (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:34381247, PubMed:36103527, PubMed:37079666). GTPase-activating protein that plays a key role in the cellular response to amino acid availability through regulation of the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:24448649, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:36103527, PubMed:37079666). Activates mTORC1 by acting as a GTPase-activating protein: specifically stimulates GTP hydrolysis by RagC/RRAGC or RagD/RRAGD, promoting the conversion to the GDP-bound state of RagC/RRAGC or RagD/RRAGD, and thereby activating the kinase activity of mTORC1 (PubMed:24095279, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:37079666). The GTPase-activating activity is inhibited during starvation and activated in presence of nutrients (PubMed:31672913, PubMed:32612235). Acts as a key component for non-canonical mTORC1-dependent control of the MiT/TFE factors TFEB and TFE3, while it is not involved in mTORC1-dependent phosphorylation of canonical RPS6KB1/S6K1 and EIF4EBP1/4E-BP1 (PubMed:21209915, PubMed:24081491, PubMed:31672913, PubMed:32612235). In low-amino acid conditions, the lysosomal folliculin complex (LFC) is formed on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, inactivates mTORC1 and maximizes nuclear translocation of TFEB and TFE3 (PubMed:31672913). Upon amino acid restimulation, RagA/RRAGA (or RagB/RRAGB) nucleotide exchange promotes disassembly of the LFC complex and liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent cytoplasmic retention of TFEB and TFE3 (PubMed:31672913). Indirectly acts as a positive regulator of Wnt signaling by promoting mTOR-dependent cytoplasmic retention of MiT/TFE factor TFE3 (PubMed:31272105). Required for the exit of hematopoietic stem cell from pluripotency by promoting mTOR-dependent cytoplasmic retention of TFE3, thereby increasing Wnt signaling (PubMed:30733432). Acts as an inhibitor of browning of adipose tissue by regulating mTOR-dependent cytoplasmic retention of TFE3 (By similarity). Involved in the control of embryonic stem cells differentiation; together with LAMTOR1 it is necessary to recruit and activate RagC/RRAGC and RagD/RRAGD at the lysosomes, and to induce exit of embryonic stem cells from pluripotency via non-canonical, mTOR-independent TFE3 inactivation (By similarity). In response to flow stress, regulates STK11/LKB1 accumulation and mTORC1 activation through primary cilia: may act by recruiting STK11/LKB1 to primary cilia for activation of AMPK resided at basal bodies, causing mTORC1 down-regulation (PubMed:27072130). Together with FNIP1 and/or FNIP2, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy (PubMed:25126726). Required for starvation-induced perinuclear clustering of lysosomes by promoting association of RILP with its effector RAB34 (PubMed:27113757). Regulates glycolysis by binding to lactate dehydrogenase LDHA, acting as an uncompetitive inhibitor (PubMed:34381247)","subcellular_location":"Lysosome membrane; Cytoplasm, cytosol; Cell projection, cilium; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytoskeleton, spindle; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8NFG4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FLCN","classification":"Not Classified","n_dependent_lines":117,"n_total_lines":1208,"dependency_fraction":0.09685430463576158},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FLCN","total_profiled":1310},"omim":[{"mim_id":"620459","title":"BIRT-HOGG-DUBE SYNDROME 2; BHD2","url":"https://www.omim.org/entry/620459"},{"mim_id":"618319","title":"PR DOMAIN-CONTAINING PROTEIN 10; PRDM10","url":"https://www.omim.org/entry/618319"},{"mim_id":"612768","title":"FOLLICULIN-INTERACTING PROTEIN 2; FNIP2","url":"https://www.omim.org/entry/612768"},{"mim_id":"610594","title":"FOLLICULIN-INTERACTING PROTEIN 1; FNIP1","url":"https://www.omim.org/entry/610594"},{"mim_id":"607273","title":"FOLLICULIN; FLCN","url":"https://www.omim.org/entry/607273"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FLCN"},"hgnc":{"alias_symbol":["BHD","MGC17998","MGC23445","DENND8B"],"prev_symbol":[]},"alphafold":{"accession":"Q8NFG4","domains":[{"cath_id":"-","chopping":"4-28_85-222_241-269","consensus_level":"high","plddt":91.2451,"start":4,"end":269},{"cath_id":"3.40.50.12430","chopping":"350-446_459-478","consensus_level":"high","plddt":91.488,"start":350,"end":478},{"cath_id":"1.10.10.1730","chopping":"498-571","consensus_level":"high","plddt":90.2408,"start":498,"end":571}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NFG4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NFG4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NFG4-F1-predicted_aligned_error_v6.png","plddt_mean":78.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FLCN","jax_strain_url":"https://www.jax.org/strain/search?query=FLCN"},"sequence":{"accession":"Q8NFG4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NFG4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NFG4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NFG4"}},"corpus_meta":[{"pmid":"17028174","id":"PMC_17028174","title":"Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17028174","citation_count":397,"is_preprint":false},{"pmid":"18234728","id":"PMC_18234728","title":"BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports.","date":"2008","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18234728","citation_count":362,"is_preprint":false},{"pmid":"15852235","id":"PMC_15852235","title":"Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15852235","citation_count":305,"is_preprint":false},{"pmid":"19850877","id":"PMC_19850877","title":"Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19850877","citation_count":192,"is_preprint":false},{"pmid":"15956655","id":"PMC_15956655","title":"High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.","date":"2005","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/15956655","citation_count":185,"is_preprint":false},{"pmid":"21209915","id":"PMC_21209915","title":"Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21209915","citation_count":144,"is_preprint":false},{"pmid":"28970150","id":"PMC_28970150","title":"FLCN: The causative gene for Birt-Hogg-Dubé syndrome.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28970150","citation_count":135,"is_preprint":false},{"pmid":"22146830","id":"PMC_22146830","title":"Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22146830","citation_count":129,"is_preprint":false},{"pmid":"14532326","id":"PMC_14532326","title":"A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14532326","citation_count":120,"is_preprint":false},{"pmid":"18974783","id":"PMC_18974783","title":"Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18974783","citation_count":113,"is_preprint":false},{"pmid":"27913603","id":"PMC_27913603","title":"The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27913603","citation_count":111,"is_preprint":false},{"pmid":"31704029","id":"PMC_31704029","title":"Cryo-EM Structure of the Human FLCN-FNIP2-Rag-Ragulator Complex.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31704029","citation_count":109,"is_preprint":false},{"pmid":"34597140","id":"PMC_34597140","title":"GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesis.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34597140","citation_count":106,"is_preprint":false},{"pmid":"15657874","id":"PMC_15657874","title":"A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15657874","citation_count":97,"is_preprint":false},{"pmid":"12907635","id":"PMC_12907635","title":"Inactivation of BHD in sporadic renal tumors.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12907635","citation_count":94,"is_preprint":false},{"pmid":"30917316","id":"PMC_30917316","title":"The Transcription Factors TFEB and TFE3 Link the FLCN-AMPK Signaling Axis to Innate Immune Response and Pathogen Resistance.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30917316","citation_count":94,"is_preprint":false},{"pmid":"27151976","id":"PMC_27151976","title":"Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1α/ERRα.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27151976","citation_count":90,"is_preprint":false},{"pmid":"19802896","id":"PMC_19802896","title":"A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19802896","citation_count":88,"is_preprint":false},{"pmid":"23150719","id":"PMC_23150719","title":"Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.","date":"2012","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/23150719","citation_count":78,"is_preprint":false},{"pmid":"20522427","id":"PMC_20522427","title":"Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.","date":"2010","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20522427","citation_count":73,"is_preprint":false},{"pmid":"20573232","id":"PMC_20573232","title":"Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20573232","citation_count":73,"is_preprint":false},{"pmid":"14769940","id":"PMC_14769940","title":"A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14769940","citation_count":69,"is_preprint":false},{"pmid":"17124507","id":"PMC_17124507","title":"Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.","date":"2006","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17124507","citation_count":65,"is_preprint":false},{"pmid":"18505456","id":"PMC_18505456","title":"Mutation analysis of the FLCN gene in Chinese patients with sporadic and familial isolated primary spontaneous pneumothorax.","date":"2008","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18505456","citation_count":65,"is_preprint":false},{"pmid":"25126726","id":"PMC_25126726","title":"FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25126726","citation_count":62,"is_preprint":false},{"pmid":"14627671","id":"PMC_14627671","title":"Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14627671","citation_count":58,"is_preprint":false},{"pmid":"17133269","id":"PMC_17133269","title":"Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17133269","citation_count":58,"is_preprint":false},{"pmid":"29848618","id":"PMC_29848618","title":"GATOR1-dependent recruitment of FLCN-FNIP to lysosomes coordinates Rag GTPase heterodimer nucleotide status in response to amino acids.","date":"2018","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29848618","citation_count":58,"is_preprint":false},{"pmid":"31404503","id":"PMC_31404503","title":"AMPK promotes induction of the tumor suppressor FLCN through activation of TFEB independently of mTOR.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31404503","citation_count":56,"is_preprint":false},{"pmid":"18794106","id":"PMC_18794106","title":"Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18794106","citation_count":51,"is_preprint":false},{"pmid":"24908670","id":"PMC_24908670","title":"Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24908670","citation_count":50,"is_preprint":false},{"pmid":"21412933","id":"PMC_21412933","title":"Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21412933","citation_count":47,"is_preprint":false},{"pmid":"26439621","id":"PMC_26439621","title":"FLCN and AMPK Confer Resistance to Hyperosmotic Stress via Remodeling of Glycogen Stores.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26439621","citation_count":46,"is_preprint":false},{"pmid":"16636660","id":"PMC_16636660","title":"The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16636660","citation_count":43,"is_preprint":false},{"pmid":"28363698","id":"PMC_28363698","title":"Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP1/AMPK pathway.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28363698","citation_count":36,"is_preprint":false},{"pmid":"20618353","id":"PMC_20618353","title":"Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations.","date":"2011","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20618353","citation_count":34,"is_preprint":false},{"pmid":"21538689","id":"PMC_21538689","title":"Birt Hogg-Dubé syndrome-associated FLCN mutations disrupt protein stability.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21538689","citation_count":33,"is_preprint":false},{"pmid":"28981362","id":"PMC_28981362","title":"The ABCs of BHD: An In-Depth Review of Birt-Hogg-Dubé Syndrome.","date":"2017","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/28981362","citation_count":31,"is_preprint":false},{"pmid":"36103527","id":"PMC_36103527","title":"Structural basis for FLCN RagC GAP activation in MiT-TFE substrate-selective mTORC1 regulation.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36103527","citation_count":31,"is_preprint":false},{"pmid":"16447066","id":"PMC_16447066","title":"Natural history of the Nihon (Bhd gene mutant) rat, a novel model for human Birt-Hogg-Dubé syndrome.","date":"2006","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16447066","citation_count":25,"is_preprint":false},{"pmid":"26083655","id":"PMC_26083655","title":"Disruption of tubular Flcn expression as a mouse model for renal tumor induction.","date":"2015","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/26083655","citation_count":23,"is_preprint":false},{"pmid":"19695222","id":"PMC_19695222","title":"Regulation of folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19695222","citation_count":22,"is_preprint":false},{"pmid":"21794948","id":"PMC_21794948","title":"Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus.","date":"2011","source":"Journal of the American Academy of Dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21794948","citation_count":22,"is_preprint":false},{"pmid":"33298956","id":"PMC_33298956","title":"Blood and lymphatic systems are segregated by the FLCN tumor suppressor.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33298956","citation_count":21,"is_preprint":false},{"pmid":"18573707","id":"PMC_18573707","title":"Birt-Hogg-Dubé (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene.","date":"2008","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/18573707","citation_count":21,"is_preprint":false},{"pmid":"27280402","id":"PMC_27280402","title":"FLCN Maintains the Leucine Level in Lysosome to Stimulate mTORC1.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27280402","citation_count":20,"is_preprint":false},{"pmid":"31272105","id":"PMC_31272105","title":"Loss of FLCN inhibits canonical WNT signaling via TFE3.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31272105","citation_count":19,"is_preprint":false},{"pmid":"33459596","id":"PMC_33459596","title":"Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33459596","citation_count":19,"is_preprint":false},{"pmid":"37182269","id":"PMC_37182269","title":"Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma.","date":"2023","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37182269","citation_count":18,"is_preprint":false},{"pmid":"28007907","id":"PMC_28007907","title":"H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28007907","citation_count":18,"is_preprint":false},{"pmid":"32049013","id":"PMC_32049013","title":"A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32049013","citation_count":18,"is_preprint":false},{"pmid":"22209521","id":"PMC_22209521","title":"Activation of AMP-activated protein kinase by MAPO1 and FLCN induces apoptosis triggered by alkylated base mismatch in DNA.","date":"2011","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/22209521","citation_count":18,"is_preprint":false},{"pmid":"23264078","id":"PMC_23264078","title":"A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.","date":"2013","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23264078","citation_count":18,"is_preprint":false},{"pmid":"36440963","id":"PMC_36440963","title":"PRDM10 directs FLCN expression in a novel disorder overlapping with Birt-Hogg-Dubé syndrome and familial lipomatosis.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36440963","citation_count":17,"is_preprint":false},{"pmid":"34267338","id":"PMC_34267338","title":"A systematic review assessing the existence of pneumothorax-only variants of FLCN. Implications for lifelong surveillance of renal tumours.","date":"2021","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/34267338","citation_count":17,"is_preprint":false},{"pmid":"25807935","id":"PMC_25807935","title":"FLCN intragenic deletions in Chinese familial primary spontaneous pneumothorax.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25807935","citation_count":17,"is_preprint":false},{"pmid":"29767721","id":"PMC_29767721","title":"BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29767721","citation_count":17,"is_preprint":false},{"pmid":"27258496","id":"PMC_27258496","title":"Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27258496","citation_count":17,"is_preprint":false},{"pmid":"22446046","id":"PMC_22446046","title":"Novel in-frame deletion mutation in FLCN gene in a Korean family with recurrent primary spontaneous pneumothorax.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22446046","citation_count":16,"is_preprint":false},{"pmid":"26516189","id":"PMC_26516189","title":"Folliculin, a tumor suppressor associated with Birt-Hogg-Dubé (BHD) syndrome, is a novel modifier of TDP-43 cytoplasmic translocation and aggregation.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26516189","citation_count":16,"is_preprint":false},{"pmid":"15579036","id":"PMC_15579036","title":"Natural history of the Nihon rat model of BHD.","date":"2004","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15579036","citation_count":16,"is_preprint":false},{"pmid":"31615547","id":"PMC_31615547","title":"Genotypic characteristics of Chinese patients with BHD syndrome and functional analysis of FLCN variants.","date":"2019","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31615547","citation_count":15,"is_preprint":false},{"pmid":"27734835","id":"PMC_27734835","title":"Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation.","date":"2016","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27734835","citation_count":15,"is_preprint":false},{"pmid":"27633572","id":"PMC_27633572","title":"Bilateral renal tumors in an adult man with Smith-Magenis syndrome: The role of the FLCN gene.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27633572","citation_count":15,"is_preprint":false},{"pmid":"28039480","id":"PMC_28039480","title":"Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28039480","citation_count":14,"is_preprint":false},{"pmid":"21496834","id":"PMC_21496834","title":"The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.","date":"2011","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/21496834","citation_count":14,"is_preprint":false},{"pmid":"28623476","id":"PMC_28623476","title":"Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.","date":"2018","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28623476","citation_count":14,"is_preprint":false},{"pmid":"26418749","id":"PMC_26418749","title":"Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26418749","citation_count":13,"is_preprint":false},{"pmid":"28499369","id":"PMC_28499369","title":"Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.","date":"2017","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28499369","citation_count":12,"is_preprint":false},{"pmid":"29357828","id":"PMC_29357828","title":"Birt-Hogg-Dubé syndrome in two Chinese families with mutations in the FLCN gene.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29357828","citation_count":12,"is_preprint":false},{"pmid":"36935552","id":"PMC_36935552","title":"Germline- and Somatic-Inactivating FLCN Variants in Parathyroid Cancer and Atypical Parathyroid Tumors.","date":"2023","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36935552","citation_count":11,"is_preprint":false},{"pmid":"30446510","id":"PMC_30446510","title":"FLCN is a novel Rab11A-interacting protein that is involved in the Rab11A-mediated recycling transport.","date":"2018","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/30446510","citation_count":11,"is_preprint":false},{"pmid":"29720200","id":"PMC_29720200","title":"Splice-site mutation causing partial retention of intron in the FLCN gene in Birt-Hogg-Dubé syndrome: a case report.","date":"2018","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29720200","citation_count":11,"is_preprint":false},{"pmid":"34711912","id":"PMC_34711912","title":"Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34711912","citation_count":10,"is_preprint":false},{"pmid":"16369488","id":"PMC_16369488","title":"Transgenic rescue from embryonic lethality and renal carcinogenesis in the Nihon rat model by introduction of a wild-type Bhd gene.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16369488","citation_count":10,"is_preprint":false},{"pmid":"22211584","id":"PMC_22211584","title":"FLCN gene-mutated renal cell neoplasms: mother and daughter cases with a novel germline mutation.","date":"2011","source":"International journal of urology : official journal of the Japanese Urological Association","url":"https://pubmed.ncbi.nlm.nih.gov/22211584","citation_count":10,"is_preprint":false},{"pmid":"19733897","id":"PMC_19733897","title":"Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms.","date":"2009","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19733897","citation_count":10,"is_preprint":false},{"pmid":"37083230","id":"PMC_37083230","title":"Role of FLCN Phosphorylation in Insulin-Mediated mTORC1 Activation and Tumorigenesis.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37083230","citation_count":9,"is_preprint":false},{"pmid":"18219524","id":"PMC_18219524","title":"Second hits in the FLCN gene in a hereditary renal cancer syndrome in dogs.","date":"2008","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/18219524","citation_count":9,"is_preprint":false},{"pmid":"37170274","id":"PMC_37170274","title":"Exons 1-3 deletion in FLCN is associated with increased risk of pneumothorax in Chinese patients with Birt-Hogg-Dubé syndrome.","date":"2023","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37170274","citation_count":9,"is_preprint":false},{"pmid":"19387735","id":"PMC_19387735","title":"Loss of heterozygosity at the FLCN locus in early renal cystic lesions in dogs with renal cystadenocarcinoma and nodular dermatofibrosis.","date":"2009","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/19387735","citation_count":9,"is_preprint":false},{"pmid":"28222720","id":"PMC_28222720","title":"Birt-Hogg-Dubé syndrome: a literature review and case study of a Chinese woman presenting a novel FLCN mutation.","date":"2017","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28222720","citation_count":8,"is_preprint":false},{"pmid":"38456787","id":"PMC_38456787","title":"The Prevalence and Radiologic Features of Renal Cancers Associated with FLCN, BAP1, SDH, and MET Germline Mutations.","date":"2024","source":"Radiology. Imaging cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38456787","citation_count":8,"is_preprint":false},{"pmid":"32184379","id":"PMC_32184379","title":"FLCN-regulated miRNAs suppressed reparative response in cells and pulmonary lesions of Birt-Hogg-Dubé syndrome.","date":"2020","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/32184379","citation_count":8,"is_preprint":false},{"pmid":"32934076","id":"PMC_32934076","title":"Quantitative genetic screening reveals a Ragulator-FLCN feedback loop that regulates the mTORC1 pathway.","date":"2020","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32934076","citation_count":8,"is_preprint":false},{"pmid":"39556154","id":"PMC_39556154","title":"Integrated systems pharmacology, molecular docking, and MD simulations investigation elucidating the therapeutic mechanisms of BHD in Alzheimer's disease treatment.","date":"2024","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/39556154","citation_count":8,"is_preprint":false},{"pmid":"31806376","id":"PMC_31806376","title":"FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31806376","citation_count":7,"is_preprint":false},{"pmid":"23416984","id":"PMC_23416984","title":"Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23416984","citation_count":7,"is_preprint":false},{"pmid":"36701047","id":"PMC_36701047","title":"FLCN-Driven Functional Adrenal Cortical Carcinoma with High Mitotic Tumor Grade: Extending the Endocrine Manifestations of Birt-Hogg-Dubé Syndrome.","date":"2023","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36701047","citation_count":7,"is_preprint":false},{"pmid":"18036795","id":"PMC_18036795","title":"Postoperative fibromatosis-type fibromas in the Bhd gene mutant (Nihon) rat.","date":"2007","source":"Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie","url":"https://pubmed.ncbi.nlm.nih.gov/18036795","citation_count":7,"is_preprint":false},{"pmid":"35176117","id":"PMC_35176117","title":"A retrospective two centre study of Birt-Hogg-Dubé syndrome reveals a pathogenic founder mutation in FLCN in the Swedish population.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/35176117","citation_count":7,"is_preprint":false},{"pmid":"33609526","id":"PMC_33609526","title":"FLCN regulates transferrin receptor 1 transport and iron homeostasis.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33609526","citation_count":6,"is_preprint":false},{"pmid":"28805452","id":"PMC_28805452","title":"Birt-Hogg-Dube Syndrome with a Novel Mutation in the FLCN Gene.","date":"2017","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/28805452","citation_count":6,"is_preprint":false},{"pmid":"30672048","id":"PMC_30672048","title":"Unilateral renal cystadenocarcinoma and nodular dermatofibrosis in a mixed-breed dog carrying a FLCN gene mutation.","date":"2019","source":"Veterinary dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30672048","citation_count":6,"is_preprint":false},{"pmid":"36410626","id":"PMC_36410626","title":"Minigene Assay as an Effective Molecular Diagnostic Strategy in Determining the Pathogenicity of Noncanonical Splice-Site Variants in FLCN.","date":"2022","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/36410626","citation_count":6,"is_preprint":false},{"pmid":"26342594","id":"PMC_26342594","title":"Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.","date":"2016","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26342594","citation_count":6,"is_preprint":false},{"pmid":"33927747","id":"PMC_33927747","title":"A Novel FLCN Intragenic Deletion Identified by NGS in a BHDS Family and Literature Review.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33927747","citation_count":6,"is_preprint":false},{"pmid":"27486260","id":"PMC_27486260","title":"Novel folliculin (FLCN) mutation and familial spontaneous pneumothorax.","date":"2016","source":"QJM : monthly journal of the Association of Physicians","url":"https://pubmed.ncbi.nlm.nih.gov/27486260","citation_count":5,"is_preprint":false},{"pmid":"26603437","id":"PMC_26603437","title":"Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?","date":"2016","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26603437","citation_count":5,"is_preprint":false},{"pmid":"28069055","id":"PMC_28069055","title":"Novel germline mutations in FLCN gene identified in two Chinese patients with Birt-Hogg-Dubé syndrome.","date":"2017","source":"Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28069055","citation_count":5,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51471,"output_tokens":9583,"usd":0.149079,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19675,"output_tokens":7612,"usd":0.144338,"stage2_stop_reason":"end_turn"},"total_usd":0.293417,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"FLCN (folliculin) physically interacts with a novel binding protein FNIP1, and this complex associates with AMPK. FNIP1 is phosphorylated by AMPK, and FLCN phosphorylation is reduced by AMPK inhibitors and rapamycin, and enhanced by FNIP1 overexpression, placing FLCN in the AMPK-mTOR signaling axis.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, in vitro phosphorylation assay, pharmacological inhibition (rapamycin, AMPK inhibitors), overexpression studies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro kinase assay, multiple orthogonal methods; independently replicated across subsequent studies\",\n      \"pmids\": [\"17028174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Homozygous BHD/FLCN knockout in mice causes early embryonic lethality (E5.5–E6.5) with defects in visceral endoderm; heterozygous knockout mice develop kidney tumors with loss of heterozygosity. BHD inactivation leads to activation of both mTORC1 and mTORC2, and PI3K-AKT pathway activation with elevated total AKT protein in kidney tumors.\",\n      \"method\": \"Conditional knockout mouse model, immunoblotting, LOH analysis, histological analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with defined molecular and cellular phenotypes, multiple orthogonal methods, replicated in human tumor samples\",\n      \"pmids\": [\"19850877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Kidney-specific FLCN knockout in mice leads to polycystic kidneys, hyperplasia, and cystic renal cell carcinoma via activation of the mTOR pathway; rapamycin treatment rescues these phenotypes, demonstrating FLCN acts upstream to suppress mTOR signaling in kidney.\",\n      \"method\": \"Conditional knockout mouse model (Ksp-Cre), rapamycin treatment, histological analysis, BUN measurements\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO with pharmacological rescue, multiple phenotypic readouts, independently replicated\",\n      \"pmids\": [\"18974783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FLCN inactivation induces nuclear localization of TFE3 transcription factor (accompanied by decreased TFE3 phosphorylation), leading to increased TFE3 transcriptional activity and upregulation of its target GPNMB. Restoration of wild-type FLCN suppresses GPNMB expression and nuclear TFE3.\",\n      \"method\": \"shRNA knockdown, stable re-expression, immunostaining, quantitative RT-PCR, immunoblotting in cell lines, mouse embryo fibroblasts, and mouse/human renal tumors\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function experiments, multiple cell types and in vivo models, multiple orthogonal methods\",\n      \"pmids\": [\"21209915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cryo-EM structure of the FLCN-FNIP2-Rag GTPase-Ragulator complex reveals that FLCN-FNIP2 adopts an extended conformation with heterodimerized Longin domains contacting Rag nucleotide-binding domains and DENN domains at the distal end. A conserved arginine on FLCN (catalytic arginine finger) is essential for its GAP activity toward RagC/D GTPases.\",\n      \"method\": \"Cryo-EM structure determination, biochemical GAP activity assays, mutagenesis of catalytic arginine\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution cryo-EM structure with biochemical and mutagenesis validation in a single rigorous study\",\n      \"pmids\": [\"31704029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of the active FLCN complex (AFC) with FLCN, FNIP2, SLC38A9 N-terminal tail, RagA(GDP):RagC(GDP·BeFx), and Ragulator shows FLCN reorients 90° relative to its inactive lysosomal conformation, breaks contact with RagA, and makes new contacts with RagC that position Arg164 for catalytic GAP activity. Disruption of AFC-specific interfaces eliminates GAP activity and causes nuclear retention of TFE3 without affecting S6K or 4E-BP1 phosphorylation.\",\n      \"method\": \"Cryo-EM structure determination, interface mutagenesis, GAP activity assay, TFE3 nuclear localization assay, S6K/4E-BP1 phosphorylation assay\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution cryo-EM with mutagenesis and functional validation demonstrating substrate-selective mTORC1 regulation\",\n      \"pmids\": [\"36103527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FLCN deficiency in muscle leads to increased mitochondrial biogenesis and a metabolic shift toward oxidative phosphorylation in a PGC-1α (PPARGC1A)-dependent manner. Re-expression of wild-type FLCN in FLCN-null kidney cancer cells suppresses mitochondrial metabolism and PPARGC1A expression.\",\n      \"method\": \"Tissue-specific conditional knockout mice (CKM-Cre, MYOG-Cre), electron microscopy (% mitochondrial area), metabolic profiling, immunoblotting, PPARGC1A double-knockout epistasis, oxygen consumption measurement\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with genetic epistasis (double KO rescue), multiple orthogonal methods, in vitro and in vivo confirmation\",\n      \"pmids\": [\"23150719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adipose-specific deletion of FLCN relieves mTOR-dependent cytoplasmic retention of TFE3, leading to TFE3 nuclear translocation and direct induction of PGC-1α/PGC-1β, driving mitochondrial biogenesis and adipose browning. This is mediated by RagC/D GTPases independently of TSC-mTOR-S6K signaling. Co-deletion of TFE3 or PGC-1β rescues the browning phenotype.\",\n      \"method\": \"Adipose-specific FLCN KO mice, TFE3 co-deletion epistasis, PGC-1β co-deletion epistasis, TFE3 nuclear localization assay, gene expression analysis, inducible PGC-1β overexpression\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO with multiple genetic epistasis rescue experiments, pathway placement, replicated by independent laboratory\",\n      \"pmids\": [\"27913603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of FLCN in adipose tissue leads to chronic hyperactivation of AMPK, which induces PGC-1α and ERRα, driving mitochondrial biogenesis, oxidative metabolism, and browning of white adipose tissue. The AMPK/PGC-1α/ERRα molecular axis mediates these metabolic effects.\",\n      \"method\": \"Adipose-specific FLCN KO mice (Adipoq-FLCN), AMPK activity assays, gene expression analysis, mitochondrial biogenesis assays, metabolic phenotyping (energy expenditure, cold exposure, HFD resistance)\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO with defined pathway placement (AMPK/PGC-1α/ERRα), multiple orthogonal functional readouts\",\n      \"pmids\": [\"27151976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FLCN-FNIP lysosomal recruitment during amino acid starvation requires GATOR1 GAP activity toward RagA/B (converting them to GDP-bound state). By binding RagA/B(GDP) and acting as GAP on RagC/D, FLCN-FNIP coordinates nucleotide status between Rag heterodimer subunits in response to amino acid availability.\",\n      \"method\": \"Lysosomal fractionation, dominant-negative and constitutively active Rag GTPase mutants, GATOR1 depletion, fluorescence microscopy, immunoblotting\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and biochemical dissection of pathway order, multiple Rag mutants, replicated by multiple orthogonal approaches\",\n      \"pmids\": [\"29848618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"During autophagy-related processes (CASM, mitophagy, xenophagy), GABARAP (but not LC3) membrane conjugation is required for TFEB/TFE3 activation. GABARAP directly binds to a previously unidentified LIR motif in the FLCN/FNIP complex, sequestering it to GABARAP-conjugated membranes, disrupting FLCN/FNIP GAP function toward RagC/D and impairing mTOR-dependent phosphorylation of TFEB.\",\n      \"method\": \"Co-immunoprecipitation, LIR motif identification and mutagenesis, GABARAP lipidation assays, TFEB/TFE3 nuclear localization, RagC/D GAP activity assays, selective autophagy genetic models\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding with LIR motif mapping, multiple orthogonal methods, functional consequence on mTOR-TFEB axis demonstrated\",\n      \"pmids\": [\"34597140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FLCN interacts with GABARAP (GABA-A receptor-associated protein), a core autophagy component. FLCN is phosphorylated by ULK1 at Ser406, Ser537, and Ser542. Loss of FLCN moderately impairs basal autophagic flux. The FLCN-GABARAP interaction is modulated by presence of FNIP1 or FNIP2 and regulated by ULK1.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation site mapping, ULK1 overexpression, autophagic flux assays (SQSTM1, MAP1LC3B, GABARAP levels), siRNA knockdown\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with site-specific phosphorylation mapping, single lab, multiple methods\",\n      \"pmids\": [\"25126726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FLCN phosphorylation at Ser62 and Ser302 is regulated by the Tsc2-mTORC1 pathway downstream of tuberin and Rheb. Downregulation of tuberin or overexpression of Rheb induces multiple FLCN phosphorylations. FLCN phosphorylation modulates its complex formation with AMPK.\",\n      \"method\": \"Immunoblotting with phospho-specific approaches, siRNA knockdown of TSC2, Rheb overexpression, AMPK co-immunoprecipitation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation mapping with upstream genetic manipulation, single lab, multiple methods\",\n      \"pmids\": [\"19695222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Pathogenic FLCN missense and in-frame deletion mutations that impair folliculin tumor suppressor function significantly disrupt protein stability (assessed in vitro). Mutations that did not impair protein stability also did not impair growth suppression activity or intracellular localization, indicating protein stability is a functional correlate.\",\n      \"method\": \"Cycloheximide chase assay, protein stability measurement, growth suppression assay in cell lines, intracellular localization by immunofluorescence, evolutionary analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro stability assays with functional validation for multiple mutants, single lab\",\n      \"pmids\": [\"21538689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Wild-type FLCN suppresses tumor development in FLCN-null renal cancer cells in nude mice in a dose-dependent manner. FLCN loss leads to downregulation of key TGF-β signaling genes including TGFB2, INHBA, THBS1, GREM1, and SMAD3. Activin A (INHBA homodimer) completely suppresses anchorage-independent growth of FLCN-null cells.\",\n      \"method\": \"Xenograft tumor assay, differential gene expression, ELISA for secreted proteins, anchorage-independent growth assay, FLCN stable re-expression\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo xenograft with molecular rescue, multiple pathway readouts, single lab\",\n      \"pmids\": [\"20573232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FLCN and AMPK act upstream of TFEB/TFE3 in the innate immune response independently of the mTORC1 signaling pathway. In C. elegans, loss of FLCN confers pathogen resistance via AMPK-dependent TFEB/TFE3 activation. In mammalian cells, loss of FLCN or AMPK activation induces TFEB/TFE3-dependent pro-inflammatory cytokine expression. LPS treatment of macrophages reduces ATP and activates AMPK with concomitant TFEB nuclear localization.\",\n      \"method\": \"C. elegans genetic epistasis (flcn-1 deletion, AMPK overexpression/deletion), mammalian FLCN KO cells, pharmacological AMPK activation, LPS treatment, nuclear localization assays, cytokine expression measurement\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cross-species genetic epistasis, multiple orthogonal approaches, both C. elegans and mammalian models used\",\n      \"pmids\": [\"30917316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In C. elegans, FLCN-1 (FLCN ortholog) loss leads to constitutive AMPK-dependent accumulation of glycogen stores, conferring resistance to hyperosmotic stress. Upon stress, glycogen is degraded to produce glycerol through GPDH enzymes. This resistance requires AMPK, glycogen synthase, and glycogen phosphorylase. Glycogen accumulates in kidneys of FLCN-deficient mice and renal tumors from BHD patients.\",\n      \"method\": \"C. elegans genetics (loss-of-function mutations, epistasis), glycogen measurement, glycerol production assay, GPDH enzyme inhibition, mouse kidney histology, human tumor tissue analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — C. elegans genetic epistasis with mammalian model validation, multiple methods, single lab\",\n      \"pmids\": [\"26439621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The AMPK-MAPO1(FNIP2)-FLCN complex is required for apoptosis triggered by O6-methylguanine DNA damage. siRNA knockdown of FLCN or FNIP2/MAPO1 suppresses sub-G1 accumulation after MNU treatment. AMPK phosphorylation after MNU occurs in an MLH1-dependent manner and requires both MAPO1 and FLCN for normal AMPK activation.\",\n      \"method\": \"siRNA knockdown, cell cycle analysis (sub-G1), AMPK phosphorylation immunoblotting, AICAR treatment, mitochondrial membrane potential assay\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA-based loss-of-function with multiple functional readouts, single lab, mechanistically placed in DNA damage apoptosis pathway\",\n      \"pmids\": [\"22209521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of FLCN in cardiomyocytes causes severe cardiac hypertrophy via mTORC1 upregulation. Flcn-deficient hearts show reduced phospho-AMPK-α (T172), elevated ATP, and increased mitochondrial function. Upregulated PPARGC1A (PGC-1α) drives excess mitochondrial metabolism, leading to AMPK inactivation and mTORC1 activation. Inactivation of PPARGC1A in Flcn-deficient hearts reduces heart mass, restores phospho-AMPK, and suppresses mTORC1.\",\n      \"method\": \"Cardiac-specific FLCN KO mice, PPARGC1A double KO epistasis, rapamycin treatment, AMPK activity assays, ATP measurement, mitochondrial function assays, echocardiography\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO with genetic epistasis (double KO rescue) and pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"24908670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Drosophila BHD homolog (DBHD) is required for germline stem cell (GSC) maintenance in fly testis. RNAi-mediated reduction of DBHD suppresses the GSC overproliferation phenotype caused by overexpression of the JAK/STAT ligand unpaired (upd) or the Dpp pathway, placing DBHD downstream or in parallel of JAK/STAT and Dpp signaling in GSC regulation.\",\n      \"method\": \"RNAi knockdown, genetic epistasis with JAK/STAT and Dpp pathway components, germline stem cell counting in fly testis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo Drosophila genetic epistasis, multiple pathway interactions tested, single lab, ortholog evidence\",\n      \"pmids\": [\"16636660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AMPK promotes expression of the FLCN tumor suppressor gene through activation of TFEB independently of mTOR. AMPK-induced FLCN expression is abolished in cells lacking TFEB/TFE3, and mutation of the putative TFEB-binding site in the FLCN promoter abrogates promoter activity, defining an AMPK-TFEB-FLCN transcriptional axis.\",\n      \"method\": \"Transcriptomic profiling, AMPK-deficient MEFs, pharmacological AMPK activators, TFEB/TFE3 double KO, FLCN promoter-luciferase reporter assay with TFEB site mutation, zebrafish exercise model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with mutagenesis, genetic KO validation, cross-species conservation, single lab\",\n      \"pmids\": [\"31404503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FLCN loss in hematopoietic cells disrupts a FLCN-TFE3 feedback loop: TFE3 normally transcriptionally activates FLCN expression, and loss of FLCN amplifies TFE3 activity. TFE3 stimulates glycogenesis by promoting expression of glycogenesis genes (Gys1, Gyg). TFE3 deletion in Flcn-KO mice reduces phagocyte expansion and lysosomal storage disorder-like phenotypes.\",\n      \"method\": \"Hematopoietic-specific Flcn KO mice, Tfe3 co-deletion epistasis, transcriptional target analysis (ChIP/gene expression), glycogen accumulation assays, histological analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with double KO rescue, mechanistic pathway placement, single lab\",\n      \"pmids\": [\"32049013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Genetic deficiency of Folliculin in mice causes misconnection of blood and lymphatic vessels due to ectopic expression of Prox1 in venous endothelial cells. Mechanistically, FLCN loss leads to nuclear translocation of TFE3, which binds a regulatory element of the Prox1 gene to enhance its venous expression.\",\n      \"method\": \"Endothelial-specific FLCN KO mice, TFE3 nuclear localization by immunofluorescence, ChIP assay for TFE3 binding to Prox1 regulatory element, Prox1 expression analysis, vascular anatomy analysis in mice and humans\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with ChIP-based mechanistic validation of TFE3-Prox1 axis, human and mouse data, multiple orthogonal methods\",\n      \"pmids\": [\"33298956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FLCN maintains the leucine level within lysosomes to stimulate mTORC1. FLCN suppression reduces lysosomal leucine content and mTORC1 activity; both effects are reversed by high leucine supplementation but not other amino acids. FLCN exerts this function by inhibiting accumulation of the amino acid transporter PAT1 on the lysosome surface.\",\n      \"method\": \"FLCN knockdown/overexpression in HEK293 cells, lysosomal amino acid measurement, mTORC1 activity assay (S6K phosphorylation), PAT1 localization by immunofluorescence, leucine rescue experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical measurement of lysosomal leucine with functional rescue, PAT1 localization studies, single lab\",\n      \"pmids\": [\"27280402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FLCN interacts with Rab11A through its C-terminal DENN-like domain. FLCN promotes loading of the amino acid transporter PAT1 onto Rab11A vesicles for recycling to the plasma membrane, preventing PAT1 accumulation on lysosomes and maintaining lysosomal amino acid levels for mTORC1 activation. In vitro GEF activity assay does not support direct FLCN-mediated modification of Rab11A nucleotide state.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping pulldown, PAT1 localization by immunofluorescence, mTORC1 activity assay, in vitro GEF assay (negative result for direct GEF activity on Rab11A), siRNA knockdown\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and functional consequences, negative GEF result explicitly noted, single lab\",\n      \"pmids\": [\"30446510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FLCN promotes Rab11A binding with transferrin receptor 1 (TfR1), which is required for TfR1 recycling between cell surface and cytoplasm. Loss of FLCN attenuates Rab11A-TfR1 interaction, delays TfR1 recycling, causes iron deficiency, and induces HIF activity. Iron supplementation reverses the HIF activation, and iron-rich diet rescues BHD phenotypes in Drosophila.\",\n      \"method\": \"Co-immunoprecipitation (Rab11A-TfR1), TfR1 recycling assay, HIF activity reporter, iron measurement, siRNA knockdown, Drosophila BHD model with dietary iron rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for complex, functional recycling assay, cross-species rescue, single lab\",\n      \"pmids\": [\"33609526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FLCN-null cells exhibit dysregulated cofilin de/phosphorylation pathways. SSH2 serine phosphatase knockdown specifically induces Caspase3/7-dependent apoptosis in FLCN-deficient cells but not in isogenic FLCN-expressing cells, identifying a synthetic lethal interaction between FLCN loss and SSH2.\",\n      \"method\": \"siRNA library screening, Caspase3/7 activity assay, cell cycle analysis, SSH1/2/3 expression measurement, FLCN isogenic cell line comparison\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — synthetic lethality screen with mechanistic follow-up in isogenic cell lines, cofilin pathway measurement, single lab\",\n      \"pmids\": [\"23416984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of FLCN in human renal tubular epithelial cells activates TFE3 and upregulates its E-box targets RRAGD and GPNMB without modifying mTORC1 activity. FLCN loss or loss of its binding partners FNIP1/FNIP2 induces a non-canonical interferon response independently of interferon, involving STAT2 recruitment to chromatin and slowed cellular proliferation.\",\n      \"method\": \"FLCN/FNIP1/FNIP2 CRISPR knockout in RPTEC/TERT1 cells, RNA-seq, ChIP for STAT2, mTORC1 activity assays, TFE3 target gene expression, proliferation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with integrated multi-omic analysis and ChIP mechanistic validation, single lab\",\n      \"pmids\": [\"33459596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of FLCN inhibits canonical WNT signaling via TFE3. FLCN deficiency decreases expression of Wnt2, Wnt7b, TCF4, LEF1, BCL9, AXIN2, and BMP4. Constitutively active β-catenin only partially rescues decreased WNT activity, whereas silencing TFE3 completely reverses the WNT activity deficit in FLCN-deficient cells, placing TFE3 as a key mediator of FLCN-dependent WNT regulation.\",\n      \"method\": \"Flcn inactivation in MEFs and human fetal lung fibroblasts, RNA-seq, TCF/LEF luciferase reporter assay, TFE3 siRNA epistasis, constitutively active β-catenin rescue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with TFE3 silencing rescue, reporter assay, single lab\",\n      \"pmids\": [\"31272105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FLCN is a novel modifier of TDP-43 cytoplasmic translocation and aggregation. FLCN directly interacts with TDP-43 through FLCN amino acids 202-299 and the RNA-recognition motif domains of TDP-43. Both exogenous and endogenous FLCN are required for TDP-43 cytoplasmic accumulation, protein aggregation, and stress granule formation.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping truncation assays, siRNA knockdown, overexpression, immunofluorescence for TDP-43 localization and aggregation, stress granule assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, loss-of-function phenotype in multiple conditions, single lab\",\n      \"pmids\": [\"26516189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AKT1 phosphorylates FLCN at a conserved site (Ser62) in an insulin-responsive manner. mTORC2-AKT1 is recruited to lysosomes by RagD, and this lysosomal RagD-mTORC2-AKT1 recruitment is an essential step for insulin-stimulated FLCN phosphorylation. FLCN phosphorylation inhibits RagC GAP activity and is required for insulin-induced mTORC1 activation and promotes tumor growth in an mTORC1-dependent manner.\",\n      \"method\": \"In vitro kinase assay (AKT1 phosphorylation of FLCN), lysosomal fractionation, RagD mutant studies, mTORC1 activity assay, FLCN phospho-site mutagenesis, xenograft tumor model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay with mutagenesis and in vivo xenograft validation, single lab\",\n      \"pmids\": [\"37083230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of hepatic FLCN activates TFEB and TFE3, promoting autophagy, reducing triglyceride accumulation, fibrosis, and inflammation in a methionine- and choline-deficient diet liver disease model.\",\n      \"method\": \"Liver-specific FLCN KO mice, TFEB/TFE3 nuclear localization assay, autophagic flux measurement, lipid accumulation assay, fibrosis scoring, inflammatory marker assessment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with functional mechanistic readouts, single lab\",\n      \"pmids\": [\"34711912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLCN missense mutants H255Y and K508R promote aberrant kidney cell proliferation. H255Y mutant transgene expression fails to rescue the multi-cystic kidney phenotype of Flcn-deficient mice. K508R mutant transgene partially rescues the phenotype in full KO mice but induces multi-cystic kidneys and cardiac hypertrophy in heterozygous KO mice, suggesting dominant negative activity of K508R on wild-type FLCN.\",\n      \"method\": \"BAC recombineering transgenic mice, Flcn-KO kidney phenotype rescue assay, histological analysis, cardiac phenotyping\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic rescue assay with multiple mutants and genetic contexts, single lab\",\n      \"pmids\": [\"28007907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FNIP2 protein stability is regulated by SCFβ-TRCP E3 ubiquitin ligase and Casein Kinase 1 (CK1) in a nutrition-dependent manner. Degradation of FNIP2 leads to lysosomal dissociation of FLCN and subsequent lysosomal association of mTOR, promoting renal cancer cell proliferation.\",\n      \"method\": \"Proteasome inhibitor experiments, β-TRCP and CK1 inhibition/knockdown, ubiquitination assays, lysosomal fractionation for FLCN and mTOR localization, proliferation assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay with upstream kinase identification and lysosomal localization consequence, single lab\",\n      \"pmids\": [\"28039480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDM10 directly binds a regulatory motif in the FLCN promoter and controls FLCN transcription. The PRDM10 Cys677Tyr variant loses affinity for this FLCN promoter element, abrogating FLCN mRNA and protein levels in human cells.\",\n      \"method\": \"DNA binding assay for PRDM10 at FLCN promoter, promoter reporter assay, inducible PRDM10 Cys677Tyr overexpression, RNA-seq, FLCN protein quantification\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding with functional consequence on FLCN expression, single lab, co-segregation in family\",\n      \"pmids\": [\"36440963\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FLCN (folliculin) is a tumor suppressor that functions as a GAP (GTPase-activating protein) for RagC/D GTPases within the FLCN-FNIP1/2 heterodimer; by catalyzing GTP hydrolysis on RagC/D at the lysosomal surface (positioning its arginine finger Arg164 for catalysis as revealed by cryo-EM structures), FLCN enables mTORC1 activation in response to amino acids and specifically controls mTOR-dependent phosphorylation of the MiT/TFE transcription factors (TFE3, TFEB), thereby regulating lysosomal biogenesis, autophagy, mitochondrial biogenesis via PGC-1α/ERRα, adipose browning, glycogen metabolism, iron homeostasis via Rab11A-TfR1 recycling, innate immune signaling via AMPK-TFEB, WNT signaling, and blood-lymphatic vessel segregation; FLCN is itself phosphorylated by both mTORC1/unknown kinases (at Ser62 and Ser302) and by AKT1 (at Ser62 in response to insulin) and by ULK1 (at Ser406, Ser537, Ser542), and its lysosomal recruitment is gated by GATOR1-dependent conversion of RagA/B to the GDP-bound state, while its sequestration by GABARAP during autophagy disrupts its GAP function to activate TFEB/TFE3.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FLCN (folliculin) is a tumor suppressor that operates at the lysosomal surface as the catalytic GTPase-activating protein (GAP) for RagC/D within the amino acid-sensing arm of the mTORC1 pathway, coupling nutrient status to a transcriptional program governed by the MiT/TFE factors TFE3 and TFEB [#4, #5, #7]. FLCN acts in an obligate heterodimer with FNIP1/FNIP2 and, in its active conformation, reorients to position a catalytic arginine finger (Arg164) for GTP hydrolysis on RagC/D; disruption of this active interface abolishes GAP activity and drives nuclear retention of TFE3 without affecting canonical S6K/4E-BP1 phosphorylation, defining a substrate-selective mode of mTORC1 control [#4, #5]. Lysosomal recruitment of the FLCN-FNIP complex is gated by amino acid availability through GATOR1-dependent conversion of RagA/B to the GDP-bound state, and FLCN coordinates the nucleotide status of the two Rag subunits by binding RagA/B(GDP) while acting as GAP on RagC/D [#9]. Loss of FLCN relieves mTOR-dependent cytoplasmic sequestration of TFE3/TFEB, and the resulting nuclear MiT/TFE activity is the common driver of FLCN-deficiency phenotypes: induction of PGC-1\\u03b1/PGC-1\\u03b2 driving mitochondrial biogenesis and adipose browning [#7], chronic AMPK\\u2013PGC-1\\u03b1/ERR\\u03b1 activation [#8], glycogen accumulation [#16, #21], cardiac hypertrophy [#18], a non-canonical interferon response [#27], WNT pathway modulation [#28], and ectopic Prox1 expression causing blood\\u2013lymphatic vessel misconnection through direct TFE3 binding to a Prox1 regulatory element [#22]. In vivo, FLCN loss activates mTORC1 (and PI3K-AKT) and produces polycystic kidneys and renal cell carcinoma that are rescued by rapamycin, establishing FLCN as an upstream suppressor of mTOR in the kidney [#1, #2]. FLCN sits within feedback and stress-responsive circuits: AMPK\\u2013TFEB transcriptionally induces FLCN expression, TFE3 itself activates FLCN transcription, and PRDM10 directly drives FLCN promoter activity [#20, #21, #34]. FLCN activity is further tuned by phosphorylation\\u2014by the TSC2-mTORC1 axis at Ser62/Ser302, by ULK1 at Ser406/Ser537/Ser542, and by insulin-responsive mTORC2\\u2013AKT1 at Ser62, the latter inhibiting RagC GAP activity to promote insulin-induced mTORC1 activation and tumor growth [#11, #12, #30]. Beyond the lysosome, FLCN engages Rab11A through its C-terminal DENN-like domain to promote recycling of PAT1 and transferrin receptor 1, maintaining lysosomal amino acid levels and iron homeostasis [#24, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that FLCN works through a defined protein complex and signaling axis was the first step in moving beyond its identification as a BHD disease gene; FNIP1 was shown to be its physical partner linking FLCN to AMPK-mTOR signaling.\",\n      \"evidence\": \"Yeast two-hybrid and reciprocal Co-IP with in vitro kinase assays and pharmacological inhibition in mammalian cells\",\n      \"pmids\": [\"17028174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the direction of FLCN's effect on mTOR\", \"Kinase phosphorylating FLCN not identified\", \"No structural or catalytic mechanism\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Whether FLCN suppresses or promotes mTOR in vivo was resolved by tissue-specific knockout showing FLCN acts upstream to restrain mTOR in the kidney, with rapamycin reversing the cystic tumor phenotype.\",\n      \"evidence\": \"Kidney-specific conditional KO mice with rapamycin rescue and histology\",\n      \"pmids\": [\"18974783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the biochemical activity by which FLCN suppresses mTOR\", \"Did not identify the relevant downstream effectors\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Germline and heterozygous mouse models established FLCN as a bona fide tumor suppressor with LOH-driven kidney tumors and showed FLCN loss activates both mTORC1/mTORC2 and PI3K-AKT, placing it broadly in growth-signaling control.\",\n      \"evidence\": \"Conditional KO mice, LOH analysis, immunoblotting of human tumors\",\n      \"pmids\": [\"19850877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting FLCN loss to AKT/mTORC2 not resolved\", \"Essential embryonic role not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The key downstream effector of FLCN was identified as the MiT/TFE transcription factor TFE3, whose phosphorylation and cytoplasmic retention depend on FLCN, with TFE3 targets (e.g. GPNMB) induced upon FLCN loss.\",\n      \"evidence\": \"shRNA knockdown and re-expression with immunostaining, RT-PCR across cell lines, MEFs, and tumors\",\n      \"pmids\": [\"21209915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The biochemical step linking FLCN to TFE3 phosphorylation not yet defined\", \"Relationship to canonical mTORC1 substrates unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Beyond mTOR, FLCN re-expression was shown to suppress tumor growth and modulate TGF-\\u03b2 pathway genes, with Activin A blocking anchorage-independent growth, broadening the tumor-suppressor output.\",\n      \"evidence\": \"Xenograft assays, differential gene expression, ELISA, anchorage-independent growth with FLCN re-expression\",\n      \"pmids\": [\"20573232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism linking FLCN to TGF-\\u03b2 gene expression not established\", \"Relationship to the TFE3 axis not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"FLCN was linked to mitochondrial metabolism by showing its deficiency drives PGC-1\\u03b1-dependent mitochondrial biogenesis and oxidative metabolism, with PGC-1\\u03b1 double-KO epistasis confirming the axis.\",\n      \"evidence\": \"Muscle-specific conditional KO mice, PPARGC1A double-KO epistasis, EM and metabolic profiling\",\n      \"pmids\": [\"23150719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FLCN loss elevates PGC-1\\u03b1 not mechanistically traced\", \"Connection to TFE3/mTOR left open\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"FLCN was tied directly to the core autophagy machinery via GABARAP binding and ULK1-mediated phosphorylation, embedding it in autophagy regulation.\",\n      \"evidence\": \"Co-IP, phospho-site mapping, ULK1 overexpression, autophagic flux assays\",\n      \"pmids\": [\"25126726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of ULK1 phosphorylation on GAP activity not defined here\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The TFE3-PGC-1 connection was placed firmly downstream of FLCN's RagC/D activity in adipose browning, independent of TSC-mTOR-S6K, by multiple epistasis rescues.\",\n      \"evidence\": \"Adipose-specific KO mice with TFE3 and PGC-1\\u03b2 co-deletion epistasis and inducible overexpression\",\n      \"pmids\": [\"27913603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not yet provide structural proof of RagC/D GAP activity\", \"Parallel AMPK contribution not reconciled\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A parallel route to FLCN-deficiency metabolism was defined through chronic AMPK\\u2013PGC-1\\u03b1\\u2013ERR\\u03b1 activation driving browning and oxidative metabolism.\",\n      \"evidence\": \"Adipose-specific KO mice, AMPK activity assays, metabolic phenotyping\",\n      \"pmids\": [\"27151976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic integration of AMPK and TFE3 arms left unresolved\", \"Cause of AMPK hyperactivation not fully traced\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A biochemical role at the lysosome was proposed by showing FLCN maintains lysosomal leucine to stimulate mTORC1 by limiting lysosomal PAT1 accumulation.\",\n      \"evidence\": \"Knockdown/overexpression in HEK293, lysosomal amino acid measurement, mTORC1 assays, leucine rescue\",\n      \"pmids\": [\"27280402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism preventing PAT1 lysosomal accumulation not yet defined\", \"Relationship to GAP activity unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The gating of FLCN-FNIP recruitment was resolved: GATOR1 GAP activity on RagA/B (GDP loading) recruits the complex, which then acts as GAP on RagC/D, coordinating nucleotide status across the Rag heterodimer with amino acid availability.\",\n      \"evidence\": \"Lysosomal fractionation, dominant-negative/constitutively active Rag mutants, GATOR1 depletion, microscopy\",\n      \"pmids\": [\"29848618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic mechanism of catalysis not yet shown\", \"How nutrient signals trigger reorientation unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The PAT1-recycling mechanism was clarified by identifying FLCN's C-terminal DENN-like domain interaction with Rab11A that loads PAT1 onto recycling vesicles, with FLCN not acting as a direct Rab11A GEF.\",\n      \"evidence\": \"Co-IP, domain mapping, PAT1 localization, mTORC1 assays, in vitro GEF assay (negative)\",\n      \"pmids\": [\"30446510\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise enzymatic role on Rab11A unresolved (no GEF activity)\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Atomic-level mechanism was established: cryo-EM of the FLCN-FNIP2-Rag-Ragulator complex revealed the heterodimer architecture and a conserved catalytic arginine finger essential for RagC/D GAP activity.\",\n      \"evidence\": \"Cryo-EM structure with biochemical GAP assays and arginine-finger mutagenesis\",\n      \"pmids\": [\"31704029\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Captured an inactive conformation; catalytic geometry not yet seen\", \"How conformational switching is triggered not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"FLCN was extended into innate immunity and stress, acting with AMPK upstream of TFEB/TFE3 independently of mTORC1 to drive pro-inflammatory and pathogen-resistance programs across species.\",\n      \"evidence\": \"C. elegans genetic epistasis and mammalian KO cells with AMPK activation and LPS treatment\",\n      \"pmids\": [\"30917316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mTOR-independent route to TFEB activation not biochemically defined\", \"Direct AMPK-FLCN-TFEB connectivity not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A transcriptional feedback loop was uncovered whereby AMPK induces FLCN expression via TFEB binding a defined FLCN promoter element, independent of mTOR.\",\n      \"evidence\": \"Transcriptomics, AMPK-deficient MEFs, TFEB/TFE3 KO, FLCN promoter-luciferase with site mutation, zebrafish\",\n      \"pmids\": [\"31404503\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts engaging the loop not fully defined\", \"Single-lab reporter evidence\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"FLCN was linked to WNT signaling, with TFE3 silencing fully reversing the WNT-activity deficit of FLCN-deficient cells, identifying TFE3 as the key mediator.\",\n      \"evidence\": \"Flcn inactivation in MEFs/fibroblasts, RNA-seq, TCF/LEF reporter, TFE3 siRNA epistasis, \\u03b2-catenin rescue\",\n      \"pmids\": [\"31272105\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TFE3 targets in the WNT pathway not mapped\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A developmental role was defined: FLCN loss drives TFE3-dependent ectopic Prox1 expression in venous endothelium, causing blood-lymphatic vessel misconnection, with ChIP showing direct TFE3 binding to a Prox1 regulatory element.\",\n      \"evidence\": \"Endothelial-specific KO mice, ChIP for TFE3-Prox1, vascular anatomy in mice and humans\",\n      \"pmids\": [\"33298956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FLCN loss is sensed specifically in venous endothelium not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A FLCN-TFE3 feedback loop in hematopoietic cells was defined where TFE3 transcriptionally activates FLCN and FLCN loss amplifies TFE3-driven glycogenesis and lysosomal-storage-like phenotypes.\",\n      \"evidence\": \"Hematopoietic-specific KO mice with Tfe3 co-deletion epistasis and transcriptional target analysis\",\n      \"pmids\": [\"32049013\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of the feedback loop across tissues not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A regulatory off-switch was identified: during selective autophagy (CASM/mitophagy/xenophagy), GABARAP conjugation sequesters FLCN-FNIP via a LIR motif, disrupting RagC/D GAP function to activate TFEB/TFE3.\",\n      \"evidence\": \"Co-IP, LIR motif mapping/mutagenesis, GABARAP lipidation assays, GAP and nuclear-localization assays\",\n      \"pmids\": [\"34597140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of GABARAP-mediated FLCN sequestration not quantified\", \"LC3 vs GABARAP selectivity mechanism not fully defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"FLCN was connected to iron homeostasis by promoting Rab11A-TfR1 binding required for TfR1 recycling; FLCN loss causes iron deficiency and HIF activation rescued by dietary iron.\",\n      \"evidence\": \"Co-IP, TfR1 recycling and HIF reporter assays, Drosophila BHD model with iron rescue\",\n      \"pmids\": [\"33609526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether iron deficiency contributes to BHD tumorigenesis unresolved\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A hepatic role was defined where FLCN loss activates TFEB/TFE3 to promote autophagy and reduce steatosis, fibrosis and inflammation in a fatty liver model.\",\n      \"evidence\": \"Liver-specific KO mice with autophagy, lipid, fibrosis and inflammation readouts\",\n      \"pmids\": [\"34711912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets driving the protective phenotype not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The catalytic mechanism of substrate-selective mTORC1 control was visualized: in the active FLCN complex, FLCN reorients 90\\u00b0 to break RagA contacts and engage RagC, positioning Arg164 for catalysis; disrupting this interface abolishes GAP activity and retains TFE3 in the nucleus without affecting S6K/4E-BP1.\",\n      \"evidence\": \"Cryo-EM of the active complex, interface mutagenesis, GAP and TFE3/S6K assays\",\n      \"pmids\": [\"36103527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for the inactive-to-active conformational switch not fully defined\", \"Basis of TFE3 vs S6K substrate selectivity at the catalytic step incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Insulin-responsive regulation of FLCN was defined: lysosomal RagD-recruited mTORC2-AKT1 phosphorylates FLCN at Ser62, inhibiting RagC GAP activity to enable insulin-induced mTORC1 activation and tumor growth.\",\n      \"evidence\": \"In vitro AKT1 kinase assay, lysosomal fractionation, RagD mutants, phospho-site mutagenesis, xenografts\",\n      \"pmids\": [\"37083230\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation of AKT1 Ser62 with TSC2-mTORC1 Ser62/Ser302 phosphorylation incomplete\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Transcriptional control of FLCN was extended by showing PRDM10 directly binds the FLCN promoter, with a pathogenic Cys677Tyr variant abrogating FLCN expression.\",\n      \"evidence\": \"PRDM10 DNA binding and promoter reporter assays, inducible variant expression, RNA-seq, family co-segregation\",\n      \"pmids\": [\"36440963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Broader regulatory network controlling FLCN expression not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single FLCN-FNIP RagC/D GAP activity is mechanistically partitioned to selectively control MiT/TFE phosphorylation versus canonical mTORC1 substrates, and how the multiple inputs (ULK1, AKT1/mTORC2, TSC2-mTORC1 phosphorylation; GABARAP sequestration; GATOR1 gating) are integrated in a given tissue.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model reconciling phosphorylation inputs with conformational switching\", \"Substrate-selectivity mechanism at the catalytic step undefined\", \"Tissue-specific weighting of mTOR-dependent vs AMPK/mTOR-independent TFE3/TFEB arms unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 24, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5, 9, 23, 33]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [24, 25]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 5, 9]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [3, 5, 7, 22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10, 11, 31]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [6, 8, 16, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 32]}\n    ],\n    \"complexes\": [\n      \"FLCN-FNIP1/2 heterodimer\",\n      \"FLCN-FNIP2-Rag-Ragulator (active FLCN complex)\",\n      \"AMPK-FNIP2(MAPO1)-FLCN complex\"\n    ],\n    \"partners\": [\n      \"FNIP1\",\n      \"FNIP2\",\n      \"RagC\",\n      \"RagA\",\n      \"GABARAP\",\n      \"Rab11A\",\n      \"TDP-43\",\n      \"AKT1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}